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In recent years, the focus of genetic epidemiology has been on diseases that are 
common and thus of major interest to public health. These are mostly complex 
diseases that have several genetic and environmental influences. The contribution 
of each disease gene to the overall risk is presumed to be small, thus large sample 
sizes are necessary to identify such loci by linkage analysis. The power of samples 
that can reasonably be recruited within a few years in one center is therefore 
limited. The popular affected sib pair (ASP) design with a few hundred ASPs is 
known to have low power for genes with small to moderate effects (e.g. Risch and 
Merikangas 1996) and many examples exist where genome scans did not show 
significant evidence for linkage (Altmüller et al. 2001). However, for many 
complex diseases several groups worldwide recruited families and the initial 
analyses of many genome scans are already published, so meta-analysis seems to 
be a realistic scenario now. A combined sample of similar studies could result in a 
sample size sufficient to find loci with smaller effects. Therefore researchers 
might be willing to cooperate towards a joint analysis.  
 
Differences between studies 
Different studies usually vary in many aspects, and the heterogeneity caused by 
numerous sources should be taken into account. These are, for example, different 
ascertainment schemes and family structures (population based family cohorts, 
nuclear families with affected sib pairs, extended pedigrees with many affecteds 
or even one large pedigree from a population isolate). Typically another obvious 
difference is the sample size. Whereas pooling automatically accounts for sample 
size differences between studies, this is not the case for methods that combine p-
values or effect estimates. For genotyping markers, different “standard panels” are 




http://research.marshfieldclinic.org/genetics) or commercial marker sets (such as 
the ABI Prism linkage mapping sets, see http://www.appliedbiosystems.com), 
sometimes with additional markers in candidate regions or genes. These panels 
vary in number and spacing of markers and their heterozygosity. In many studies, 
environmental and other covariables are collected, but not in a consistent manner 
across studies. These covariates may or may not be included in the initial analysis, 
but are rarely published in detail. Even the phenotype definition varies between 
studies, e.g. it may be possible to use either a quantitative phenotype or a discrete 
trait for the same disease (like hypertension). Especially in psychiatric disorders, 
the diagnosis is sometimes difficult because no objective measure of disease 
exists, and different diagnostic schemes are used (such as ICD 10 and DSM IV). 
The different ethnic background of study populations can lead to genetic 
heterogeneity between samples, especially in combination with different 
ascertainment criteria and phenotype definitions. As for a single linkage study, 
locus heterogeneity seriously diminishes the power of meta-analysis. However, 
very little is known about its extent in complex diseases, and one would expect 
that at least some common disease genes can be identified in a combined sample. 
Hardly any work has been done on the question if and when it is appropriate to 
aggregate evidence across genetic linkage studies and to test whether samples are 
homogenous enough. This applies to both genetic homogeneity (same disease 
gene responsible in all study populations, same phenotype) and variability caused 
by study design, for instance family structures. A test for homogeneity was 
proposed by Babron et al. (2001), but its usefulness for the typical sample sizes, 
where it might have very low power, was questioned by the authors. The 
differences in study design also pose methodological problems as they preclude 
simple methods of combining evidence for linkage across studies. For example, 
just adding model-based two-point LOD scores over families (from different 
studies) is not possible if different markers at different locations were genotyped, 
or different genetic models were used for analysis. And traditional methods of 
fixed or random effects meta-analysis that produce an overall effect size estimate 
require that the same parameter or effect size measure is estimated and available 
from all studies, which is usually not the case if different study designs were used.  
 For genetic linkage studies, a combination of tests of the same null hypothesis 




locus. This implies that genotype data of the same marker must be available in all 
studies or that equivalent information about the inheritance at the specific locus is 
available in all studies through multipoint linkage methods (e.g. Kruglyak et al. 
1996). But even with multipoint methods, the estimated inheritance pattern 
depends on the number, positions, and heterozygosity of the genotyped markers in 
a region (and the availability of genotyped founders), all of which determine the 
information content. For regions with low information content, the estimated 
sharing of alleles identical by descent (IBD) between relatives is biased towards 
the null hypothesis under several commonly used IBD estimation methods 
(Schork and Greenwood 2004). With different marker panels genotyped, there is a 
systematic difference in IBD estimates between studies even with the same study 
design and underlying genetic model, which is neither considered by most 
published meta-analysis methods, nor by simple pooling. Therefore, pooling of 
raw data should not be considered the gold standard of meta-analysis (for biases 
from simple pooling see also Bravata and Olkin 2001). 
 
Previous applications of meta-analyses to linkage studies of complex diseases 
Interest in meta-analysis and the awareness of the necessity of collaboration and 
meta-analysis seems high in the human genetics community (Conneally 2003), 
and the number of published meta-analyses for complex diseases has been rising 
steadily over the last years. Examples for meta-analyses of linkage genome scans 
include a meta-analysis of published genome scan data for autism (Badner and 
Gershon 2002b), meta-analyses of genome scans for hypertension and blood 
pressure (Koivukoski et al. 2004), cleft lip/palate (Marazita et al. 2004), psoriasis 
(Sagoo et al. 2004), rheumatoid arthritis (Choi et al. 2006), body mass index 
(Johnson et al. 2005) and age-related macular degeneration (Fisher et al. 2005). A 
two-stage approach has been employed by Demenais et al. (2003) who conducted 
a meta-analysis of four European genome scans for type 2 diabetes, first using the 
GSMA method (Wise et al. 1999, which is presented in detail in chapter 2.3.1) for 
the whole genome as a “screening tool” for the most promising regions and then 
pooled the individual genotype and phenotype data and family information for a 
combined analysis of only those chromosomes that were significant in the GSMA. 
Such a combined analysis of individual data has also been perfomed for whole 




Sclerosis Genetics Cooperative 2001) and type I diabetes (Cox et al. 2001) where 
three groups each combined their samples. It has also been used for a combined 
analysis of data from eight linkage genome scans for body mass index (Wu et al. 
2002). For some diseases, consortia were formed to facilitate and prospectively 
plan the pooling of data. They have proposed standardized study protocols and 
consistent methods for diagnosis and data collection (CSGA asthma consortium 
(Xu et al. 2001), The ADHD Molecular Genetics Network (2000)).  
 
Publication bias 
Publication bias, the usual concern about meta-analyses that negative results are 
less likely to be published, could be a smaller problem in the context of genome 
scans. These are always large, expensive projects which are bound to be 
published, and some interesting results are obtained in virtually every scan. 
Exceptions could be those studies conducted by industry. One special form of 
publication bias could occur in genome scans when detailed results are only given 
for regions that show some evidence for linkage and genome wide results are only 
presented as small figures. Including only those scans or regions with a significant 
result in a meta-analysis would lead to serious bias. In this case, it is necessary to 
request the complete and exact results from the authors. Also linkage studies for 
candidate regions might not be published if negative. Thus, a thorough search for 
all relevant studies, including unpublished ones or those presented only at 
scientific meetings is an important first step in a meta-analysis. Tests for 
publication bias and sensitivity analysis are also advisable (for some general 






In this thesis, the following objectives will be addressed: 
A) Give an overview of existing meta-analysis methods both in general and 
specifically for linkage genome scans (chapter 2). 
B) Describe in detail a new statistical method for meta-analysis of genetic 
linkage studies (chapter 3). This method was first proposed by Loesgen et 
al. (2001). 
C) Compare the power of the proposed new method with existing methods 
and explore effects of different markers sets and sample sizes on the power 
of meta-analysis (chapter 4). This simulation study was published in 
Dempfle and Loesgen (2004). 
D) As a first application of the proposed weighted meta-analysis, a meta-
analysis of a binary phenotype, i.e. asthma affection status, is performed 
(chapter 5). This was carried out in the context of the Genetic Analysis 
Workshop 12 (GAW 12) and published in Loesgen et al. (2001). 
E) A meta-analysis of the quantitative phenotype adult height is performed 
(chapter 6), using a different meta-analysis methodology. This was 
motivated by the results of a linkage genome scan of this phenotype in the 
Framingham Heart Study, which was published as Geller/Dempfle et al. 
(2003, joint first authorship).  
In chapter 7, the implications of this research for meta-analysis of linkage studies 










2.1 Overview of statistical methods for meta-analysis in general  
In the classical meta-analysis context (e.g. clinical trials) there is typically one 
pre-specified effect of interest for which estimates or tests from several studies are 
combined (Hedges and Olkin 1985). In genome scans for linkage on the other 
hand, statistical tests, for example on sharing of alleles identical by descent (IBD) 
between relatives, are considered at many loci across the whole genome, and the 
interest is in the location of the largest test statistic. Some methods for the classic 
case of one specific effect of interest are reviewed first, before coming to the 
genome scan situation. 
 The aim of a meta-analysis is to take advantage of an increased sample size 
for a more precise estimate or for a more powerful statistical test (or both) than in 
the individual samples. In general, it can be distinguished between p-value based 
methods, which are purely tests of significance and those to combine effect 
estimates, often together with the estimation of a confidence interval and a 
significance test.  
 
Methods based on the combination of p-values 
Overviews of p-value methods are given by Folks (1984) and Hedges and Olkin 
(1985). If k independent studies test equivalent null hypotheses H0i, i=1, ..., k, a 
combined test of the omnibus null hypothesis H0: “all H0i are true” can be 
constructed. Let pi be the one-sided p-values from continuous test statistics 
(possibly different statistics in the different studies) used to test the individual H0i. 
Then the pi are distributed as independent uniform variables on the interval [0,1] 
under the null hypothesis. This fact is used for most combined tests. The first such 
test was proposed by Tippett (1931, as cited by Hedges and Olkin (1985)), which 




smaller than 1 - (1 - α)1/k is α, which gives a level α test. This procedure is 
admissible for tests from the exponential family (Folks 1984).  
 Another often used procedure was proposed by Fisher (1932), who 
transformed the uniformly distributed p-values to χ2 variables and combine these. 
If p has a uniform distribution, then -2 ln(p) has a χ2 distribution with 2 degrees of 







ln2 , which is distributed as a χ2 
random variable with 2k degrees of freedom. This test procedure is also 
admissible for tests from the exponential family (Folks 1984). Elston (1991) 
shows that Fisher’s method is asymptotically optimal among essentially all 
methods of combining independent tests.  
 Two related modifications of Fisher’s method are given by Olkin and Saner 
(2001) and Zaykin et al. (2002) who propose trimming some p-values, either all 
above a certain threshold or the n largest (or smallest, with n<k) and give the 
correct distributions of the resulting test statistics. This method is more powerful 
than Fisher’s original method for alternatives where only some of the k null 
hypotheses are false, while Fisher’s method which uses all p-values will rather 
detect departures from the omnibus null hypothesis when most of the individual 
null hypotheses are false. 
 A third method that uses the uniform distribution of p-values is to transform 
them via the standard normal distribution (attributed to Stouffer et al. 1949 by 
Hedges and Olkin (1985)). If Zi=Φ-1(pi) (with Φ-1 the inverse of the standard 








1 is distributed as a standard 

















is also distributed as a standard normal (the unweighted inverse normal method is 
the case of setting all weights equal to 1). These weights can reflect study 
characteristics such as sample size with more weight for larger, more precise 
studies and less weight for small studies. This procedure is also admissible for 




p-values, it is more powerful against alternatives where most of the individual null 
hypotheses are false than in cases where only some of them are false. 
 
Methods based on effect estimates 
Meta-analysis methods that use effect estimates usually result in a combined 
effect estimate together with a confidence interval and a significance test. In 
general, the effect estimates from single studies are weighted proportional to their 
precision for a combined estimate. Depending on the research question and study 
designs of the individual studies, appropriate effect size measures, e.g. odds ratios 
or relative risks, differences in survival between treatment and control group or 
the number of alleles shared IBD between sib pairs have to be extracted from each 
study. Following Sutton et al. (2000), let Ti be the observed effect sizes in i=1, … 
, k independent studies, each with variance vi. Let θi be the underlying population 
effect sizes for which Ti are estimates from each study, i.e.  
iii eT += θ , with ei being a random sampling error that has mean 0 and variance vi. 
In a fixed effects model, all population effect sizes are assumed equal, i.e.  
θ1 =… = θk = θ, where θ is the true common underlying effect size. Then a fixed 
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These weights (inversely proportional to the variance in each study) minimize the 







If a sufficient number of studies are combined, T can be assumed to be normally 
distributed, which leads to a canonical confidence interval and significance test. 
 If the assumption of a common underlying effect size θ is not justified, 
random effects meta-analysis can be used. Here, heterogeneity between studies is 
included in the model and the study-specific (true) effects θi are assumed to come 
from a random distribution of effect sizes with a fixed mean θ and variance στ2:  
ii τθθ += . 
Therefore the model includes both within and between study variation, with 




iii eT ++= τθ . 



















In practice, estimates of vi and στ2 are used for weighting. 
 Estimation of between-study heterogeneity is an important step in meta-
analysis, which is also performed to decide whether studies are combined using 
fixed or random effects meta-analysis. This is usually done by Cochran’s Q-
statistic (Cochran 1937 as cited by Sutton et al. (2000)), which is defined as 








ii TTwQ  
 Under the null hypothesis of homogeneity, Q is distributed as a χ2 variable 
with k-1 degrees of freedom. However, if only a small number of studies is 
combined such heterogeneity tests usually have very low power (Sutton et al. 
2000). Stratified analyses for subgroups of studies defined by plausible causes of 
heterogeneity may be a useful addition to formal heterogeneity tests. 
 The results of a meta-analysis are often presented graphically. The most 
typical form of display is the so called forest plot in which much information can 
be conveyed succinctly (Sutton et al. 2000). The point estimates of the relevant 
effect size measure together with a 95% confidence interval are shown for each 
study, together with the combined estimate and its confidence interval. The size of 
each study is often represented additionally as the size of the box denoting the 
point estimate. 
 
2.2 The special situation of meta-analysis of linkage genome scans 
In genetic linkage studies, the choice and definition of appropriate effect sizes can 
be difficult. For affected sib pairs (ASP) the number of alleles shared IBD at a 
marker locus is often the parameter of interest, e.g. in the popular mean test of 
Blackwelder and Elston (1985) and related test statistics. However, if the study 
design includes also other affected relative pairs, e.g. cousins, the underlying 
effect size measure will be different. For quantitative traits, the effect size can be 




relates the phenotypic differences between siblings to the IBD sharing. But since 
there is no general agreement as to which study design should be used for linkage 
analysis of complex diseases, and even less which test is preferred for a particular 
study design, the researcher is confronted with the problem that published studies 
of the same disease use different statistics which are based on completely different 
effect size measures. Therefore it is often not possible to extract estimates of a 
common effect size measure from different studies. Besides, the results are 
usually reported as statistical tests (often termed LOD score, but not necessarily 
following the same distribution as a parametric LOD score (Morton 1955; Nyholt 
2000) and it is often not possible to transform this back to a parameter estimate 
and its variance. Lastly, since a genome scan includes not only one statistical test 
but several hundreds along the genome, it is common to report only results that 
reached some level of significance in detail in the paper and not results for all 
positions tested. So the necessary information for a meta-analysis usually will 
have to be requested from the authors of the original studies. 
 The goal of a meta-analysis of genome scans is not only to get a more 
powerful test for any specific locus but to identify the loci or genetic regions with 
the strongest overall evidence for linkage in the genome. Even though technically 
hypothesis tests are considered, a linkage genome scan is rather a method to 
generate a hypothesis (determine a region for subsequent analysis, including 
finemapping and functional studies) than to test one or more specific hypotheses 
(like the involvement of a particular candidate gene). The results of genome wide 
analyses are never taken as a definite proof for the involvement of a specific gene. 
Therefore, claiming linkage to a region which in the end turns out to be false is 
often considered less serious than missing a true linkage. 
 The growing interest in meta-analysis of linkage studies has led to the 
adaptation of standard statistical methods and the development of new specific 
methodology, which will be briefly reviewed below. In general, methods for 
linkage genome scans can be divided into those for pooling raw data and those for 
genuine meta-analysis that combine statistics from different studies (see table 1 
for some differences between pooling and meta-analysis). Meta-analysis methods 
can be further divided into those that combine significance tests (e.g. in the form 
of p-values) and those that combine effect estimates and then test the significance 





Table 1: Some differences between pooling and meta-analysis of genetic linkage studies. 
Pooling Meta-Analysis 
 Needs complete raw data (family structures, 
genotypes and phenotypes of all individuals) 
 Needs only intermediate results, e.g. LOD 
scores (but these usually for all loci) 
 All available information can potentially be 
used 
 Only aggregated information is available 
 Automatically accounts for sample size  Possible to account for sample size 
 Often only possible for same markers  Methods to account for different markers can 
be developed  
 Can use same linkage analysis method  Has to cope with different linkage methods 
 Can use methods that account for family 
structures, covariates or heterogeneity on an 
individual or family level 
 Can use such information only on a per-study 
basis, not individually 
 
 Pooling of linkage genome scan data would mean to use the complete family 
structures and genotypes and phenotypes of all individuals in all studies in one 
combined analysis which treats data as if it was derived from one single study, 
while meta-analysis uses only the results, such as LOD scores or effect estimates 
along the genome, of each study. Pooling of raw data automatically uses all 
available information and thus might be the most powerful way to combine 
linkage data, but this is not necessarily the case. Multipoint methods will enable 
the combined analysis even if different marker sets were genotyped in the 
different studies. However, without consideration of systematic differences, 
pooling may yield spurious or paradoxical results (Bravata and Olkin 2001). 
Especially in unbalanced designs, this can lead to counterintuitive conclusions, if 
e.g. in clinical trials a treatment is beneficial in two (unbalanced) studies, and a 
pooling of the data shows that in the pooled study groups the treatment does not 
appear beneficial. This phenomenon is known as Simpson’s paradox (Simpson 
1951, as cited by Bravata and Olkin 2001) and can be avoided by weighting 
results appropriately before combining. In linkage analysis, unbalanced designs 
may not be such a serious problem, but systematic genetic heterogeneity between 
studies may be a concern that is better addressed by meta-analysis than simple 
pooling. But even for a meta-analysis, the availability of the complete genotype 
data (instead of just LOD scores or other summary data) would be helpful, since 




and facilitates incorporation of study characteristics (such as family structures) or 
covariates into the meta-analysis. 
 
2.3 Overview of existing methods for meta-analysis of linkage genome scans 
 
2.3.1 Meta-analysis methods specifically for linkage studies 
2.3.1.1 Genome Search Meta-Analysis (GSMA) 
A meta-analysis method specifically developed for linkage genome scans is the 
Genome Search Meta-Analysis (GSMA) by Wise et al. (1999), which is a non-
parametric rank method to evaluate the combined evidence for linkage in several 
genome scans. As input from each study, it allows any linkage test statistic and, 
for each chromosomal region, measures the relative significance of the results 
across different studies. For GSMA, the chromosomes are divided into bins of 
roughly equal size, each bin containing at least one measurement per study. Thus 
the complete results of the genome scan have to be available, not just the locations 
and LOD scores of significant linkage regions. The authors suggest approximately 
30 cM intervals as bins to combine typical human genome scan results, yielding 
about 120 bins. For each scan, the result corresponding to the smallest level of 
significance in each bin is recorded; this could be the highest LOD score in the 
interval or the smallest p-value. Within each study, the bins are ranked according 
to this result, and the ranks within a bin are summed across all studies. Wise et al. 
(1999) give the distribution of this rank sum under the null hypothesis that there is 
no susceptibility locus within the bin. This assumes that results of different bins 
are stochastically independent. No combined effect estimate can be computed 
with this method. The different studies do not need to be analyzed with the same 
statistical method (e.g. the results of parametric LOD score analyses can be 
combined with non-parametric allele sharing statistics), and it is not necessary to 
have the same markers genotyped in different studies. Wise et al. (2001) extend 
their method to work with studies not covering the whole genome, e.g. candidate 
gene studies, but in this situation the distribution under the null has to be obtained 
by simulation. The same would be necessary to incorporate weights, e.g. for study 
size, which is not considered in the originally proposed method. As the procedure 
is very computer intensive for a simulation study, the investigation in the 





2.3.1.2 Multiple scan probability (MSP) 
Badner and Goldin (1999) proposed a method to combine p-values across studies 
by calculating the probability for a set of attained p-values in a genetic region. The 
procedure is proposed for situations where not the complete results of the whole 
genome scans are available, but just the usually published smallest p-values with 
their locations. Each p-value is corrected for multiple testing by accounting for the 
length of the investigated interval using the dependence structure of genetic 
linkage along a chromosome (Lander and Schork 1994). So if for one study the 
smallest p-value attained on a certain chromsome arm is known, this will be 
corrected for the genetic length of this chromosome arm. The resulting adjusted p-
values are then combined using Fisher’s procedure. As such, this type of meta-
analysis does not take into account different sample sizes between studies. This 
method cannot yield a location estimate, but will give an adjusted meta-analysis p-
value which applies to the largest region included in the meta-analysis. This 
method was further refined and applied to bipolar disorder and schizophrenia 
(Badner and Gershon 2002a) and also to autism (Badner and Gershon 2002b).  
 
2.3.2 Methodological adaptations and applications of general meta-analysis 
methods to linkage studies  
2.3.2.1 Fisher’s method for combining p-values 
For the evaluation of several independent tests of the same null hypothesis, the 
before mentioned procedure of combining p-values by Fisher (1932) is available. 
Under the null hypothesis, that there is no disease gene at a particular locus, p-
values p1, ... , pn from n independent studies are uniformly distributed on the 
interval [0,1], and -2 ln pi is distributed as a χ2 random variable with 2 degrees of 







ln2 , is distributed as a χ2 
random variable with 2n degrees of freedom. When using this method, studies can 
be analyzed with different statistical methods, i.e. p-values can be derived from 
different test statistics, but have to be available at the same loci.  
 A note on the use of Fisher’s method in the context of linkage analysis was 
given by Province (2001). Since many nonparametric linkage methods truncate 




interpreting a nonparametric LOD of 0 as a p-value of 0.72 (instead of 0.5), to 
avoid bias when including results from such studies.   
 Fisher’s method to combine p-values (Fisher 1932), has been applied in 
genetic epidemiology by Allison & Heo (1998) who used this method to combine 
p-values from single point analyses at different markers across a candidate region 
in studies of obesity. Guerra et al. (1999) compared Fisher’s method with the 
pooling of raw data on Genetic Analysis Workshop 11 simulated data (Greenberg 
et al. 1999). Finally, Wu et al. (2002) analyzed eight samples from four ethnic 
groups in a study on obesity and used Province’s  modification (2001) of Fisher’s 
method (interpreting a nonparametric LOD of 0 as a p-value of 0.72). A similar 
approach was applied recently in a meta-analysis of genome scans for fasting 
glucose, insulin, and insulin resistance (An et al. 2005). 
 
2.3.2.2 Truncated product method (TPM) 
Zaykin et al. (2002) present a generalization of Fisher’s method for combining p-
values in the context of genetic analyses. For this method, only p-values below a 
certain threshold τ (e.g. 0.05, naturally accounting for habits of reporting only 
‘significant’ results) are considered. They derive the exact distribution of the 
product of these p-values under the null by conditioning on the number of p-
values less than τ. This is derived from the fact that the number of p-values less 
than τ (from k independent tests) follows a binomial distribution Bin(k, τ) under 
the global null hypothesis. Again, these p-values can be obtained by different 
methods but must be given for each study on every marker intended for meta-
analysis. TPM has been proposed for genetic studies, but has not been applied to 
linkage genome scans yet. 
 
2.3.2.3 Fixed and random effects meta-analysis 
The general concept of obtaining combined estimates of relevant effect size 
measures through fixed or random effects meta-analysis have also been proposed 
in the context of genetic linkage analysis, both for single locations (e.g. candidate 
genes) and whole genome scans. They require the availability of sensible effect 
estimates and their variances for each study at each genetic location. These are 




extracted from the published data (as is usually the case for other types of studies, 
e.g. clinical trials). Therefore such methods are only feasable if the complete 
individual data for each study are available to conduct sensible primary analyses 
which yield such parameter estimates for all samples. As mentioned above, even 
if the raw genotype data from several studies is available, it might be sensible to 
use a meta-analysis which accounts for possible heterogeneity instead of pooling 
the data in one combined analysis without regard for systematic differences such 
as different genotyped marker sets. Approaches that aim at combining effect 
estimates in model-free linkage analysis mostly use the number of alleles identical 
by descent (IBD) between relative pairs as the common effect across studies (e.g. 
Wu et al. 2002). Gu et al. (1998) present a method how to derive and combine 
IBD estimates even from different sib pair designs (e.g. concordant affected and 
discordant) in a random effects model. Further developments of this approach are 
found in Gu et al. (1999) and Gu et al. (2001). Similarly, McQueen et al. (2005) 
used the complete genotype data of eleven linkage studies of Bipolar Disorder to 
perform the same statistical analysis for each sample, test heterogeneity of IBD 
estimates and finally combine them in a random-effects model. Goldstein et al. 
(1999) proposed combining IBD estimates in a fixed effects meta-analysis, by 
weighting estimates with the inverse of their variance. For quantitative 
phenotypes, a sensible effect size measure from linkage analysis can be the 
Haseman-Elston regression coefficient (Haseman and Elston 1972). These were 
combined in fixed and random effects meta-analyses by Etzel and Costello 
(2001), Iyengar et al. (2001) and Jacobs et al. (2001) in the context of the Genetic 
Analysis Workshop 12 (Meyers et al. 2001) where the complete, individual data 
of four genome scans and five candidate studies on asthma were available. Etzel 
and Guerra (2002) investigated this approach in some more detail. A different 
effect size measure for quantitative traits was used by Hejimans et al. (2005), who 
initially analyzed serum lipid levels in each of four samples separately using an 
inverse regression method (Sham et al. 2002; implemented in Merlin-Regress, 
Abecasis et al. 2002), which yields locus-specific heritabilities and corresponding 
standard errors. These were then combined across samples by use of a random 





2.3.3 Heterogeneity tests for linkage studies 
In a traditional meta-analysis framework, estimation of between-study 
heterogeneity is an important step. This is usually done by Cochran’s Q-statistic 
(Cochran 1937 as cited by Sutton et al. (2000)) which was introduced in chapter 
2.1, or variants of this. The specific form of this heterogeneity test if the effect of 
interest is the mean IBD sharing among affected sib pairs has been given e.g. by 
Gu et al. (1998; 2001) and Goldstein et al. (1999).  
 This type of heterogeneity test needs the study specific effect estimates and 
variances, just as the estimation of a common effect in a fixed or random effects 
meta-analysis. Therefore it is usually only possible to perform for linkage genome 
scans if the original genotype data are available from all studies. If no effect size 
estimates but just measures of significance (e.g. LOD scores) are available from 
each genome scan, such a test is not possible. In theory, it is possible to use the 
fact that a one-tailed p-value is a function of sample size and effect size, to 
construct a heterogeneity test using just p-values, but this is only valid if all 
studies have the same sample size (Hedges and Olkin 1985, p 126) and thus of 
limited use. Similar approaches to inferring an effect estimate from a p-value have 
been proposed (Rosenthal and Rubin 2003) but these are subject to analogous 
inadequacies (Kraemer 2005; Hsu 2005). So in practice a heterogeneity test based 
just on measures of significance is not adequate if different study designs, test 
statistics and sample sizes are used and would be of limited applicability.  
 In a similar spirit, Zintzaras and Ioannidis (2005) proposed a generalization of 
Cochrans Q statistic for the GSMA method, using ranks instead of effect 
estimates in each of 120 bins. Ranks are only measures of the relative significance 
of a genomic region in relation to all other regions in the same study. As such, 
ranks for each bin across studies are independent of sample size, study design or 
statistical test used. This test is supposed to be performed for each bin, leading to 
120 heterogeneity tests for a genome-wide meta-analysis. For one bin, let Ri and 
wi be the rank and weight for study i and R the average rank across all studies, 
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Two similar metrics were also proposed, and in all cases, the significance of the 




comparison to using effect size measures has not been assessed. This procedure 
for heterogeneity testing has been used by Malhotra et al. (2005) in a meta-
analysis of genome scans for lipid traits in African Americans. 
 An additional concern in genome-wide linkage studies is the question for 
which loci heterogeneity tests should be performed, since studies usually differ in 
the markers that are genotyped. One approach would be to test heterogeneity for 
each locus for which a combined linkage test (or effect size estimate) is intended, 
e.g. at every cM position along the genome, thus leading to approximately 3600 
tests for a whole genome scan (based on sex-averaged genetic length of the 
human genome (Kong et al. 2002)). But since such homogeneity tests usually 
have very low power if only a small number of studies is combined (Sutton et al. 
2000), performing so many tests might lead to an unacceptably high amount of 
both false positive and false negative results. Other options have also been 
proposed, such as one test per chromosome arm to account for the considerable 
variation in location of the maximum linkage peak in small samples. Therefore 
just the maximum linkage statistic at each chromosome arm for each study could 
be included in a test for heterogeneity (Babron et al. 2001).  
 In conclusion, heterogeneity tests for linkage genome scans have low power, 
and are rarely feasible as they need the complete individual data from all studies. 
Additionally, not enough research has been done on the question for which loci 
such tests should be best performed. Stratified analyses, e.g. based on subgroups 
of studies of the same ethnicity or population may be more appropriate. 
 
2.3.4 Graphical display of results  
A graphical display of meta-analysis results in relation to individual results can be 
done in a similar fashion as the presentation of the primary genome scan results, 
using a graph of the obtained LOD scores or p-values against the genetic location 
along the genome (for examples see the applications in chapters 5 and 6). This 
makes it possible to simultaneously depict the results for the complete genome. 
However, contrary to the graphical presentation of meta-analysis results in 
traditional cases where just one effect is of interest, the precision of the individual 
studies will not be apparent from such a display. Results for the most interesting 




a forest plot, if the relevant effect size estimates and confidence intervals are 
available for all studies. 
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For genetic linkage analysis of complex traits, non-parametric methods are often 
used, which do not require specification of a genetic model. These model-free 
methods evaluate the number of alleles shared IBD between affected relatives. 
One of the most popular study designs for linkage analysis of complex diseases is 
the affected sib pair (ASP) design, where families with at least two children 
affected with the disease of interest are ascertained. The children and their parents 
(if available) are genotyped with highly polymorphic microsatellite markers or 
large numbers of single nucleotide polymorphism (SNP) markers spread 
throughout the genome. Non-parametric linkage analysis is then performed, e.g. 
using the mean test of Blackwelder and Elston (1985), which is based on the 
number of alleles shared IBD between an ASP. Such tests are implemented in 
commonly used software such as Genehunter (Kruglyak et al. 1996), Allegro 
(Gudbjartsson et al. 2000) and Merlin (Abecasis et al. 2002). The popular NPLpairs 
statistic as implemented in Genehunter is a generalization of the mean test, which 
is equivalent to the mean test for ASPs and a fully informative marker and 
generalizes to other family structures such as larger sibships or affected cousins. 
For a marker which is not fully informative in a given family, the genotypes at 
neighboring markers are used to estimate IBD sharing, based on the known 
dependence structure of linkage along a chromosome. Such multipoint methods, 
using Hidden Markov Models are used to incorporate information from flanking 
markers and allow the calculation of the linkage statistic also for positions 
between markers (Kruglyak et al. 1995).  
 In an ASP study, let πi(t) be the number of alleles shared IBD by sib pair i at 
location t (in cM). Then πi(t) follows a trinomial distribution under the null 
hypothesis of no linkage and takes values 0, 1 and 2 with probabilities ¼, ½ and 
¼. Thus the expectation of πi(t) is 1 and its variance ½. For most genetic locations 
πi(t) is not directly observable, so likelihood-based methods were developed to 
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estimate πi(t) conditional on all marker data on one chromosome (Risch 1990b; 
Kruglyak et al. 1996). The NPLpairs test statistic at location t for a study j (j = 1, ..., 
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 Under the null hypothesis of no linkage at locus t, this is the standardized 
mean allele sharing. Thus, Zpairs, j(t) is asymptotically distributed as a standard 
normal (Kruglyak et al. 1996), if the inheritance pattern at this position can be 
completely inferred (fully informative marker). 
 For meta-analysis using effect estimates, π(t), the mean number of alleles 
shared IBD between ASPs is the appropriate effect size for which a combined 
estimate is required. Zpairs, j(t) is a standardized estimate of this variable for study j, 
multiplied by jn . The variance of π(t) is proportional to 1/nj, so weighting this 
estimate with n (or equivalently Zpairs, j with jn ) is optimal to minimize the 
variance of the combined estimate as in a fixed effects meta-analysis (Hedges and 
Olkin 1985). Thus, a combined linkage test statistic can be defined, by weighting 
each study specific NPL statistic with jn .  
 At a marker that is not fully informative, the expectation under the null 
hypothesis is used to estimate the IBD sharing in Zpairs, which makes it a 
conservative test and leads to a biased estimate of IBD sharing under the 
alternative (Kong and Cox 1997; Schork and Greenwood 2004). In the extreme 
case, where a family is completely uninformative (e.g. not genotyped for a 
marker) this leads to an estimated IBD sharing of 1 for an affected sib pair, as 
would be expected under the null hypothesis. This so called “perfect data 
approximation” (Kruglyak et al. 1996) will always result in reduced power for 
locations between genetic markers, since here the inheritance pattern has to be 
estimated. For single studies, this is also evident in the fact that NPL scores 
always peak at markers (see figure 3 in chapter 4) and drop between markers, 
contrary to parametric LOD scores which are usually higher between markers. 
Since NPL scores are preferentially evaluated at the genotyped markers in 
individual studies, this power loss between markers is most relevant if marker 
spacing is large (and heterozygosity low). For meta-analysis however, studies 
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which used different sets of markers are included and thus results at all genetic 
locations are relevant. Uncertainty on the inheritance pattern therefore reduces 
power for non-parametric linkage analysis and can be interpreted as reducing the 
effective sample size of a study (Guo and Elston 2000). Examples for this loss of 
power caused by ambiguity of the inheritance pattern at a genetic location are 
described in the simulation study and shown in figures 2 and 3 (chapter 4). 
Unweighted pooling of NPL scores across studies, or weighting just with study 
size, is therefore not optimal when different markers are genotyped and the 
amount of information on inheritance in families varies between studies at each 
locus. A measure for the uncertainty of the inheritance pattern at a genetic 
location is the information content (IC) as first proposed by Kruglyak and Lander 
(1995) and refinded by Kruglyak et al. (1996). This uses the information-theoretic 
entropy as a measure of residual uncertainty in a probability distribution, here the 
distribution of inheritance vectors for a pedigree, which describe the inheritance 
pattern at a genetic location within a family. The entropy at a genetic location t is 
defined as  
∑−=
i
ii tPtPtE )(log)()( 2  
where Pi(t) is the probability of the ith possible inheritance vector for a family. In 
the absence of genotypic data, the probability distribution is uniform over all 22n-f 
equivalence classes of inheritance vectors (with n denoting the number of non-
founders and f the number of founders in a family), thus the entropy in this case is 
E0=2n-f. The information content for a family is then defined as  
.)(1)( 0EtEtIC −=  
The entropy is an additive measure and is summed over all pedigrees in a sample. 
With this definition, IC is a general measure of available information on the 
inheritance pattern in the included families which does not depend on any specific 
linkage test statistic and always lies between 0 and 1, taking the value 1 for a fully 
informative marker and the value 0 in the absence of any genotype information 
(Kruglyak et al. 1996). The product of IC and sample size therefore is a 
reasonable approach to approximate the effective sample size. Using IC to 
approximate the effective sample size has the advantage that this is standard 
output of most multipoint linkage analysis programs (e.g. Genehunter, Allegro or 
Merlin) and therefore may be available for a meta-analysis, while other measures 
NEW META-ANALYSIS METHOD 
___________________________________________________________________________________________________ 
 22
of information which are based on individual genotypes will not be accessible for 
meta-analysis. 
 Recently, the loss of power in non-parametric linkage analysis caused by less 
than perfect information about inheritance has also been discussed in detail by 
Schork and Greenwood (2004) which lead to a lively debate (Cordell 2004; 
Mukhopadhyay et al. 2004; Visscher and Wray 2004; Sieberts et al. 2004; 
Abecasis et al. 2004). As several authors pointed out, the extent of this power loss 
depends on the test statistic used and on the specific implementation in a software 
algorithm. Specifically, the NPLpairs statistic (as implemented in Genehunter 
(Kruglyak et al. 1996)) and the equivalent mean test (as implemented e.g. in 
SIBPAL/S.A.G.E. 2004) suffer from a relevant loss of power due to the “perfect 
data approximation” used that treats uninformative (or partly informative) families 
inappropriately. This is overcome by non-parametric linkage statistics which were 
proposed by Kong and Cox (1997), termed allele sharing LOD scores, which are 
implemented e.g. in Genehunter-Plus (Kong and Cox 1997), Allegro 
(Gudbjartsson et al. 2000) and Merlin (Abecasis et al. 2002). Franke and Ziegler 
(2005) suggested a weighting scheme for individual families to improve the mean 
test, by weighting each affected sib pair with the appropriate marker informativity. 
A comparison of the power of their proposed approach with the power of the 
Kong and Cox (1997) non-parametric LOD scores has not been done, yet. A 
comparison of this test statistic with Holmans’ possible triangle test (Holmans 
1993) and other extensions of the mean test (Knapp 2006) shows that it performs 
poorly for realistic genetic models, especially in situations with low marker 
informativity, for which it was designed (Knapp 2006). Sensible linkage test 
statistics therefore should not treat un-informative or partly informative families 
as though they would provide evidence for the null hypothesis of no linkage but 
rather consider that they provide only limited or no information at all for the test, 
thus reducing the effective sample size (Mukhopadhyay et al. 2006). If such test 
statistics are used, the loss in power is reduced. However, the effective sample 
size of a study is still diminished if families in the sample are un-informative or 
partly informative for a marker. And even if genetic markers are highly 
polymorphic and all individuals within a family are genotyped, the multipoint 
approximation used to calculate the test statistic even for locations between 
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markers (which have to be considered in meta-analysis), always leads to a 
reduction of the effective sample size. 
 Consequently, a combination of NPL scores is proposed which uses the 
following different weights: study size (equals pooling of the raw data in the case 
of ASPs), information content, and if the information content is not available an 
exponential function of the distance to the next marker (which provides a simple 
means to describe the loss in information content between markers). These 
methods for weighted meta-analysis were first proposed in Loesgen et al. (2001) 
and further refined and evaluated in Dempfle and Loesgen (2004). 
 For any locus t let ICj(t) denote the information content in study j, and dtj be 
the distance (in cM) from t to the closest genotyped marker in study j. Then the 
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 The unweighted combined tests statistic is used for comparison in the 
simulation study in the next chapter and analogously ZIC and ZDist are defined 
without the weighting factor for study size. With these definitions, the weighted 
scores are again distributed as standard normal under the null hypothesis, so 
appropriate p-values can be calculated. The normality assumption is confirmed in 
the following simulation study (chapter 4) on unlinked chromosomes both for 
weighted and unweighted Z-scores. 
 The implementation of the proposed meta-analysis is very simple: it uses the 
NPL scores at regular intervals (e.g. every 1 cM) for each study, which are 
standard output of all programs for multipoint non-parametric linkage analysis. If 
the NPL scores are only available at genotyped markers, they may be interpolated 
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for the desired regular locations between markers. Depending on the desired 
weighting scheme and extend of available data, it is also necessary to obtain the 
sample size and study specific IC at the same intervals as the NPL scores (which 
is also standard output from e.g. Genehunter, Allegro or Merlin). If IC is not 
accessible, the locations of genotyped markers can be used to calculate the 
distance between each evaluated position and the closest marker. The combined 
NPL statistic is then calculated from these ingredients (usually at regular intervals 
again) and the p-value can be derived from the standard normal distribution.  
 If other test statistics instead of NPL scores have been calculated in the 
original studies, these may be included through the inverse normal method. P-
values or LOD scores from other test statistics are converted to Z-scores via the 
normal distribution and can then also be usefully weighted and combined. The 
application of the more sophisticated weighting schemes with IC or a distance 
measure is of course dependent on the availability of the necessary data and if 
these cannot be obtained, a weighting just with sample size will still be possible 
and valuable. 
 General concerns regarding tests for heterogeneity in genome-wide linkage 
studies have been addressed in the preceding chapter and apply to this method as 
well. Especially low power if only relatively few studies are combined (which will 
be the case for most diseases) in combination with severe multiple testing make 
such tests very unreliable (Babron et al. 2001). The parameter of interest in non-
parametric ASP studies is the mean IBD sharing and as a test of heterogeneity, 
Cochran’s Q statistic can be used (Gu et al. 1998). However, a valid estimate of 
the variance of the mean IBD sharing without the assumption that the null 
hypothesis is true requires the locus-specific, family-wise IBD estimates 
(McQueen et al. 2006), which are usually not available for a meta-analysis. From 
just the NPL scores themselves, which are standardized for each study, no valid 
estimate and variance of the relevant parameter can be calculated, especially 
because information content and thus effective sample size varies across genetic 
locations. Another drawback is that in practical applications the sample often 
contains a mixture of similar but not identical family structures, such as more than 
two affected siblings or additionally some affected cousins. More distant relatives 
have lower expected IBD sharing and thus there is not one single relevant 
parameter (such as π(t)) that applies to all families or all samples in a meta-
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analysis. All this makes a formal heterogeneity test practically infeasible if only 
summary results (such as NPL scores) and not individual data are available for a 
meta-analysis. If potential sources of heterogeneity, such as different ethnicities 
between study samples, are known, a useful strategy would instead be to perform 
meta-analyses for presumably more homogeneous subsets of samples from the 
same population as well as for all study samples. Other known study-specific 
covariates, such as average disease severity of ascertained cases or average age-
of-onset, could also be used to define clinically relevant subgroups which may be 
genetically more homogeneous and perform subgroup specific meta-analyses. 
 As a graphical display, a plot of the individual and the meta-analysis NPL 
scores in one figure (for each chromosome or genome-wide) will allow useful 
comparisons. Examples of such figures can be seen in the applications to the 
phenotypes asthma and height (chapters 5 and 6). Forest plots, as are used for 
meta-analyses of just one specific parameter of interest, will not be practical for 
genome-wide analysis.  
 The proposed methods are widely applicable for meta-analysis of linkage 
studies. Multipoint NPL scores are calculated in many affected sib pair studies for 
complex disease. Other multipoint test statistics can be used via the inverse 
normal method. The necessity to have results for all loci is not unique to the 
proposed method, but arises in similar form in any other meta-analysis method for 
genome wide linkage studies as statistical tests of the same hypothesis, i.e. linkage 
to the same locus, have to be combined. Here, Badner’s method (Badner and 
Gershon 2002b) is an exception that can be applied to the usually published data 
which still is often only the significant p-values. GSMA needs at least one value 
of each study in each bin which is rarely the case if only interesting values are 
reported. However, more and more researchers distribute the detailed results of 
their analysis via the internet, like NPL scores for each marker tested (as in a 
psoriasis scan by Nair et al. 1997), where the multipoint statistics at regular 
intervals (as in a stature and BMI genome scan by Perola et al. 2001) and the 
information content could be included. Besides, it is a long standing scientific 
tradition to keep data and intermediate results and to give other researchers the 
opportunity to verify the reported results by making materials and data available. 
Many scientific journals (e.g. Nature, Science, The American Journal of Human 
Genetics, Human Molecular Genetics, or Molecular Psychiatry) stress this 
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obligation in their instructions for authors. The need to provide all original data to 
reviewers and, after publication, to all interested scientists was emphasized in the 
context of microarray gene expression studies by Perou (2001) and deposition of 
microarray data in public databases is now explicitly demanded by most journals 
(MIAME standard, Brazma et al. 2001). His reasoning, that other scientists need 
the chance to check the alleged conclusions and to gain additional insight by a re-
analysis applies equally to genome wide linkage analysis. It should therefore be a 
matter of course to obtain at least the detailed results for all markers from the 





4  Simulation Study: Exploring Effects of Different Markers 





4.1 Simulated model 
Whole genome scan data was simulated to compare the power of different 
methods of meta-analysis. The simulations are intended to reflect a realistic 
scenario, which represents studies by four separate research groups undertaken in 
the same or closely related populations. This means that a clinically homogeneous 
sample with the same underlying genetic model of disease, such as disease allele 
frequencies and penetrances, is simulated for all studies. The simulations 
correspond to a situation where collaboration between groups is anticipated or 
planned in advance, so that study protocols, especially with regard to 
ascertainment and diagnosis, are similar or even standardized. Therefore the 
affected sib pair (ASP) design was chosen for all studies. The studies differ in 
their sample size (i.e. the number of ASP) and in the marker panels that are 
genotyped. The emphasis of this simulation study is on the effect of using 
different marker panels and the resulting variation in information content at each 
locus. 
 A binary trait dependent on a bi-allelic disease locus is modeled. The 
population frequency of disease allele D is 0.1 and that of the low-risk allele or 
group of alleles d equals 0.9. The penetrances are 0.4 for genotype DD, 0.1 for 
genotype Dd and 0.025 for genotype dd, so the disease alleles act multiplicatively 
with a genotypic relative risk (GRR) of 4. This results in a λsib of 1.54 and a 
λoffspring of 1.48 (Risch 1990a) and an expected IBD sharing at the disease locus of 
0.597 (see table 2). To investigate whether the results generalize to other trait 
models, two other scenarios were also simulated. These were a recessive model 
with a very similar effect (expected IBD sharing 0.594, penetrances 0.05, 0.05 and 




carriers) and a multiplicative model with a relative risk of only 3.5 (expected IBD 
sharing 0.576, penetrances 0.05, 0.175 and 0.613). 
 
Table 2: Parameters of different simulation scenarios. 
Scenario Multiplicative GRR 4 Recessive Multiplicative GRR 3.5 
Penetrance DD 0.4 0.6 0.613 
Penetrance Dd 0.1 0.05 0.175 
Penetrance dd 0.025 0.05 0.05 
Prevalence of 
disease 
0.042 0.056 0.078 
λsib 1.537 1.287 1.392 
λoffspring 1.479 1.088 1.360 
E(IBD|ASP) 0.597 0.594 0.576 
 
 1000 replicates of affected sib pair data of 80 families on four different 
marker panels A, B, C, D were simulated, which represent the four different 
studies. Marker loci are spaced every 5 or 15 cM on two 90 cM chromosomes 
with 2 or 6 equifrequent alleles at each marker (such as SNP or microsatellite 
markers). See table 3 for the combination of these parameters. The disease gene is 
always located at position 46 cM of chromosome 1, but as the position of the first 
marker varies, so does the distance of the closest marker to the disease locus as 
shown in figure 1.  
 
Table 3: Parameters for the simulation of study types A to D. 













to the disease 
locus (cM) 
A 80 15 6 8 7 
B 80 5 2 3 2 
C 40+40 15 6 0 1 













Figure 1: Simulated Marker Maps. Total length is 90 cM, disease locus is at position 46 cM. 
 
 
Chromosome 2 is “unlinked”, i.e. it does not have a disease gene. To investigate 
the influence of study size, data on marker panels C and D were split into two 
groups of 40 sib pairs each, referred to as C_1, C_2, D_1, and D_2, respectively. 
Simulations were performed with the genome scan simulation program 
SIMSCAN developed by S. Loesgen (unpublished). The core algorithm renders 
this program especially suited for the evaluation of methodology for affected 
relative designs. The basis of the following comparisons in the simulation study is 
a ‘standard analysis’ of each simulated study with Genehunter NPLpairs (Kruglyak 
et al. 1996) in 1 cM steps (for ASPs and a fully informative marker, the NPLpairs is 
equivalent to the mean test of Blackwelder and Elston (1985)). Combined 
analyses of the four simulated studies were done with the proposed weighting 
methods for Z-scores (unweighted, weighted by size, information content, 
distance or combinations of these), with the GSMA, Fisher’s method and TPM as 
described in the previous chapter. As the GSMA method uses only the relative 
significance (i.e. the rank) of a region compared to all other regions in the 
respective study, the p-values depend on the number of bins. To get a good 
approximation of a full genome scan, the results of the linked chromosome in 
each study are used together with the results of 39 replicates of an “unlinked” 
chromosome, for a total of 120 bins in each study. As expected this gives indeed 





4.2 Results of the simulation study 
4.2.1 Effect of recombination and low informativity on power 
The power of the different meta-analysis methods to detect linkage to the 
simulated disease locus is compared. The power of a statistical test under a 
specific alternative (here the simulated disease model) is determined by the 
sample size (in this case the number of informative sib pairs). The maximal power 
of an affected sib pair linkage study with a given sample size, and a given test 
statistic, will be achieved when the inheritance pattern at the disease locus can be 
correctly inferred in every family. This is the case if each sib pair is fully 
informative. In reality, this upper bound will not be reached, as not every meiosis 
at every marker is informative, and additionally there is recombination between 
the disease locus and the closest marker. However, this overly optimistic approach 
is frequently used in sample size calculations (e.g. Risch and Merikangas 1996) as 
this is a straightforward method and corrections for realistic situations are difficult 
to model. The theoretical power of the NPLpairs test with full information at the 
disease locus (which is the maximal power achievable with this test statistic) is 
given in table 4 for different significance levels and sample sizes for scenario 1 
and in table 5 for different sample sizes in scenarios 1 to 3 at a significance level 
of 0.00074. Under the assumptions mentioned above, a single study of 80 ASP 
has little power to establish linkage in scenario 1 (less than 25% at α = 0.00074, 
the threshold for “suggestive” linkage as defined by Lander and Kruglyak (1995)), 
but a combined sample of 320 ASP can reach a good power of about 80% even at 
a stringent significance level of α = 0.000022 (“significant“ linkage) and over 
95% power at α = 0.00074. Scenarios 1 and 2 with different genetic models have 
very similar expected power, whereas the multiplicative genetic model with the 
smaller effect in scenario 3 has much smaller power. 
 
Table 4: Theoretical power (in %) of the mean test for ASPs in a single study with the simulated 
disease parameters of scenario 1 at different significance levels (with a fully informative marker 
locus completely linked to the disease locus). 
Number of ASPs α = 0.01 α = 0.00074 α = 0.000022 
40 27.13 6.98 0.82 
80 54.82 22.74 4.73 





Table 5: Theoretical power (in %) of the mean test for ASPs in a single study of scenarios 1 to 3 




Scenario 1:  
multiplicative, GRR = 4
Scenario 2:  
recessive, GRR = 4
Scenario 3: 
multiplicative, GRR = 3.5 
80 22.74 21.05 10.31 
320 95.95 94.82 75.44 
 
 Recombination between the disease locus and a marker will diminish the 
chance to detect linkage. The incorporation of recombination rates in the power 
calculation for the mean test is for example implemented in the TDT-Power 
Calculator (primarily designed for TDT power calculation, but also capable of 
calculating the power of the mean test for ASPs) by Chen and Deng (2001). Note 
that even though marker allele frequencies are required to be specified in this 
program, they are only used in the TDT power calculation, but not in the power 
calculation for the mean test, which assumes that the number of alleles identical 
by descent at the marker locus can be unequivocally inferred for each sib pair, as 
with a fully informative marker. Table 6 gives the estimated power under scenario 
1 with different numbers of ASPs and recombination fractions. A distance of 1 
cM between the disease locus and a fully informative marker does not affect the 
power very much, but a distance of 7 cM will result in an important loss of power, 
e.g. from about 51% to 30% with 80 ASPs at a significance level of 0.01 or from 
73% to 31% for 320 ASPs at a level of 0.000022. 
 
Table 6: Power (in %) of the mean test for ASPs in a single study under scenario 1 at different 
recombination fractions between disease locus and a fully informative marker (calculated with the 
TDT-Power Calculator) at different significance levels. 
Number of ASPs Distance (cM) α = 0.01 α = 0.00074 α = 0.000022 
80 1 50.90 19.91 3.86 
80 7 30.04 8.31 1.07 
320 1 99.21 93.89 73.31 
320 7 90.39 67.11 31.80 
 
 Another, more realistic method to estimate the power of a linkage study is 
implemented in the ASP Power Calculator by Krawczak (2001) which uses a 
likelihood ratio test for allele sharing in sib pairs. Here, the incomplete 




incorporated. However, the program is restricted to just four preset significance 
levels, and the power is calculated for an implicit two-point analysis. Power 
estimates are presented for the restricted likelihood ratio test, which is an 
extension of the mean test for not fully informative sib pairs and should therefore 
be comparable in terms of power with the NPLpairs method from Genehunter 
(Kruglyak et al. 1996). Table 7 shows the results for different marker settings 
comparable to the marker closest to the disease locus in this simulation setup at 
α=0.01 under scenario 1. The difference to the theoretical estimates of maximal 
power is striking. Depending on the distance and the information content of the 
marker the power for 80 ASPs ranges from less than 20% to 42% instead of the 
maximal power of 55% at this significance level. Due to the loss of information, a 
bi-allelic marker (with equifrequent alleles) yields only about half the power of a 
six-allelic marker at the same locus (compare columns 1 and 2). Almost the same 
reduction can be seen if the marker is 7 instead of 1 cM away from the disease 
locus (see columns 1 and 3). 
 
Table 7: Estimated power (in %) of a single study under scenario 1 (10000 simulations of ASP 
Power Calculator, restricted model) at a significance level of 0.01, for different distances between 
the disease locus and the closest marker locus and different numbers of equifrequent marker 
alleles. 
Number of ASPs 1 cM, 6 alleles 1 cM, 2 alleles 7 cM, 6 alleles 
40 21.1 9.6 12.2 
80 41.7 18.9 24.2 
320 97.1 71.0 82.2 
 
 Summarizing, the power is overestimated by Risch’s formula as it assumes 
full information at the disease locus while the ASP Power Calculator is too 
pessimistic for multipoint analysis. The size of these deviations can be seen in the 
analysis of the individual simulated studies (table 8). The power is calculated as 
the fraction of simulations in which the p-value for the combined sample is below 
a given level, and thus the null hypothesis is correctly rejected. Here, the lowest p-
value in an interval of 30 cM around the disease locus is considered. This is a 
practical compromise between counting any significant result on the whole 
chromosome and counting only the disease locus itself as a correct positive result. 
The first approach would be too optimistic as further investigations (e.g. fine 




finding. The latter approach would be too restrictive as it is well known that there 
is considerable variation in the location of the strongest result (Cordell 2001). 
This choice is also reasonable as GSMA can only localize a trait to within a bin 
(usually about 30 cM) and it would be unfair to require the other methods to 
localize it more precisely. If power is based on an interval of 14 cM around the 
disease locus, all results are between 0.2 to 2.6 percentage points lower (at the 
suggestive level), but with no clear pattern of differences between the meta-
analysis methods. 
 
Table 8: Power of single studies at different significance levels (percentage of replicates with a p-
value below the respective level at a locus within 15 cM in both directions of the true disease 
locus, out of 1000 replicates) and average information content (IC) of each study at the disease 
locus under scenario 1. 
Study type α = 0.01 α = 0.00074 α = 0.000022 Average IC 
A 34.3±1.5 6.3±0.8 0.5±0.2 0.583 
B 45.1±1.6 12.6±1.0 1.2±0.3 0.703 
C 43.3±1.6 11.2±1.0 1.6±0.4 0.775 
D 43.9±1.6 10.9±1.0 1.3±0.4 0.722 
C_1 21.4±1.3 3.9±0.6 0.3±0.2 0.776 
C_2 20.9±1.3 3.4±0.6 0.3±0.2 0.775 
D_1 21.6±1.3 3.2±0.6 0.0±0.0 0.722 
D_2 21.2±1.3 3.1±0.5 0.1±0.1 0.721 
 
 When there is less than perfect information (which is always the case), the 
NPLpairs procedure is conservative under both the null and alternative hypotheses, 
but for different reasons. Under the null hypothesis, the variance of the test 
statistic is overestimated (Kong and Cox 1997), thus leading to a conservative 
test. Under the alternative (at the position of a disease gene) the test statistic will 
additionally be downward-biased, resulting in power loss. Thus low information 
in effect distorts the overall result in the direction of no linkage. This occurs 
because allele sharing is estimated given all marker data by using the distribution 
of the number of alleles identical by descent under the null hypothesis (Kruglyak 
et al. 1996). The expectation under the alternative of linkage would in general be 
higher. So in the extreme case when there is no information about the actual 
inheritance at a locus in a family, this is considered equivalent to the case when it 
can be observed that an ASP shares one allele identical by descent, which is what 




evidence against linkage, whereas in the former case there is in fact no evidence at 
all since nothing has been observed at all. This effect can be quite drastic. Figure 2 
shows the information content (IC, as calculated by Genehunter (Kruglyak et al. 
1996)) along the linked chromosome in one replicate of studies A and C each, 
both having markers with 6 equifrequent alleles, spaced 15 cM apart. The disease 
locus is highlighted. At the locations of the markers, the information content is 
almost 90%, and it drops to less than 60% between markers.  


















Figure 2: Information content along the linked chromosome for a replicate of study type A 
(dashed line) and C (solid line). The position of the disease locus is denoted by a dot. 
 
 The corresponding NPLpairs statistics for this replicate are shown in figure 3. 
For study C, which has a marker close to the disease locus and therefore high 
information content at this position, the NPLpairs score is 4.03 at the disease locus 
(p-value=0.000025) and 4.21 at the next marker (p-value=0.000011). For study A, 
on the other hand, the maximal score is only 3.0 (p-value=0.00297) at the flanking 

















Figure 3: NPL Score along the linked chromosome for a replicate of study type A (dashed line) 
and C (solid line). The position of the disease locus is denoted by a dot. 
 
 Table 8 shows the power of the single studies of type A-D and their 
respective average information content at the disease locus in scenario 1. The 
distance between the disease locus and the closest marker can be seen in table 3. 
As expected, they all have considerably less power than under the assumption of 
full information but more power than estimated by Krawczak’s method. At a 
suggestive α level, power estimates for 80 simulated sib pairs are between 6% and 
13%, compared to 23% maximum power. As power for this level cannot be 
calculated by the ASP Power Calculator, the power at a significance level of 0.01 
is also compared. Here, the maximum power would be 55%, estimates in this 
simulation study vary between 34% and 45%, while Krawczak’s program gives 
20% to 42%, and Chen and Deng’s program calculates 30% to 51%.  
 For the microsatellite markers, the power is lower in study type A (where the 
closest marker is 7 cM from the disease locus and the average IC across families 
at the disease locus is 0.58) than in study type C (closest marker 1 cM from 




these two designs is due to the combined effect of less than perfect information 
and recombination between disease locus and the closest marker, which cannot be 
disentangled in this setup. The multipoint analyses of the SNP maps B and D have 
similar power and average IC at the disease locus, comparable to the 
microsatellite design C. Splitting the samples C and D into two studies of 40 pairs 
each decreases the power by more than half, at stringent α levels even to a quarter. 
 The power of single studies under scenarios 2 and 3 is given in table 9. As 
expected, scenario 2 has similar power to scenario 1 and scenario 3 has lower 
power. 
 
Table 9: Power of single studies at different significance levels (percentage of replicates with a p-
value below the respective level at a locus within 15 cM in both directions of the true disease 
locus, out of 1000 replicates) under scenarios 1 to 3 at a significance level of 0.00074. 
Study type Scenario 1:  
multiplicative, GRR = 4 
Scenario 2:  
recessive, GRR = 4 
Scenario 3: 
multiplicative, GRR = 3.5 
A 6.3±0.8 6.3±0.8 4.2±0.6 
B 12.6±1.0 10.0±0.9 4.1±0.6 
C 11.2±1.0 11.8±1.0 5.4±0.7 
D 10.9±1.0 10.5±1.0 4.8±0.7 
C_1 3.9±0.6 3.8±0.6 2.3±0.5 
C_2 3.4±0.6 3.6±0.6 1.7±0.4 
D_1 3.2±0.6 3.6±0.6 1.3±0.4 
D_2 3.1±0.5 3.9±0.6 1.5±0.4 
 
 
4.2.2 Power of meta-analysis methods 
The power of the different meta-analysis methods and weighting schemes to 
combine four studies of equal size (80 ASPs each) is shown in table 10. Again, it 
is always below the maximum power for 320 ASPs. The highest power, close to 
80% at the suggestive level, is achieved by the Z-score combination methods 
proposed here. Among them, weighting with information content or distance 
parameter seems to have slightly better power at all levels. The p-value based 
methods (Fisher, TPM, GSMA) have around 65% power at the suggestive level. 
Here, the lowest power is estimated for Fisher’s method, but at the level of 





Table 10: Power of combined analyses of four studies A-D (N=80 each, scenario 1, multiplicative, 
GRR=4) at different significance levels (percentage of replicates with a p-value below the 
respective level at a locus within 15 cM of the true disease locus out of 1000 replicates). 
Method α = 0.01 α = 0.00074 α = 0.000022 
Zunweighted 96.6±0.6 77.3±1.3 37.5±1.5 
ZIC 97.0±0.5 79.8±1.3 39.7±1.5 
ZDist 96.9±0.5 79.5±1.3 39.6±1.5 
GSMA 87.8±1.0 62.8±1.5 26.2±1.4 
Fisher 87.5±1.0 62.4±1.5 28.3±1.4 
TPM 94.0±0.8 68.2±1.5 27.9±1.4 
 
 For the recessive scenario with a very similar effect size, the Z-score 
combination methods have a power of 70% (unweighted) to 73% (weighted with 
IC or distance) at a suggestive level, while Fisher’s method and GSMA have 
about 57% and TPM 63% power (table 11). In a scenario with a smaller effect 
size (multiplicative with GRR of 3.5), the Z-score methods reach 42% to 46% 
power, while Fisher’s method has 28%, GSMA 31% and TPM 33% power. 
 
Table 11: Power of combined analyses of four studies A-D (N=80 each) at different significance 
levels for scenarios 2 and 3 (percentage of replicates with a p-value below the respective level at a 
locus within 15 cM of the true disease locus out of 1000 replicates). 
Method Scenario 2, recessive Scenario 3, multiplicative, GRR 3.5 
 α = 0.00074 α = 0.000022 α = 0.00074 α = 0.000022 
Zunweighted 69.9±1.5 30.6±1.5 42.4±1.6 10.7±1.0 
ZIC 72.4±1.4 33.4±1.5 45.8±1.6 11.9±1.0 
ZDist 73.3±1.4 33.8±1.5 46.1±1.6 12.2±1.0 
GSMA 56.4±1.6 23.1±1.3 30.9±1.5 7.4±0.8 
Fisher 57.0±1.6 22.7±1.3 28.5±1.4 6.9±0.8 
TPM 62.6±1.5 23.7±1.3 33.4±1.5 6.5±0.8 
 
 The results for different study sizes are given in table 12. Here, the general 
picture is similar. One should keep in mind that, in each simulation, these are the 
same families as before, just split up differently, thus the power reached in table 
12 has to be compared with that in table 10. However, only for the Z-score 
combination methods weighted additionally with the number of affecteds, the 
results are exactly the same (the small difference when weighting with IC occurs 




marginally). For all methods that do not account for study size, the power is 
slightly lower in the setting with the smaller samples. The Z-score methods 
disregarding sample size lose around 3 percentage points in power (in the 
following presentation differences in power will still be reported as percentage 
points using the % symbol for convenience). Fisher’s method seems to be the least 
robust in this respect, the power drops from 62% to 53%. For TPM the difference 
is about 4%, for GSMA only about 2% (at the suggestive level).  
 
Table 12: Power of combined analyses of six studies A-D2 (N=80 or 40) of scenario 1 
(multiplicative, GRR=4) of different study size at different significance levels (percentage of 
replicates with a p-value below the respective level at a locus within 15 cM of the true disease 
locus out of 1000 replicates). 
Method α = 0.01 α = 0.00074 α = 0.000022 
Zunweighted 96.1±0.6 75.7±1.4 35.8±1.5 
ZSize 96.6±0.6 77.3±1.3 37.5±1.5 
ZIC 96.7±0.6 76.9±1.3 36.9±1.5 
ZIC+Size 96.8±0.6 80.1±1.3 39.9±1.5 
ZDist 96.7±0.6 76.6±1.3 37.0±1.5 
ZDist+Size 96.9±0.5 79.5±1.3 39.6±1.5 
GSMA 87.5±1.0 60.5±1.5 24.1±1.4 
Fisher 81.9±1.2 53.0±1.6 20.5±1.3 
TPM 93.0±0.8 64.3±1.5 24.5±1.4 
 
 This picture is similar for the other simulated disease models (table 13), 
where the power of Fisher’s method drops from 28% to 23% (multiplicative 
model with smaller effect) or from 57% to 49% (recessive model) at the 
suggestive level. The power of TPM drops by 3% and that of GSMA by about 





Table 13: Power of combined analyses of six studies A-D2 (N=80 or 40) at different significance 
levels for scenarios 2 and 3 (percentage of replicates with a p-value below the respective level at a 
locus within 15 cM of the true disease locus out of 1000 replicates). 
Method Scenario 2, recessive Scenario 3, multiplicative, GRR 3.5 
 α = 0.00074 α = 0.000022 α = 0.00074 α = 0.000022 
Zunweighted 69.2±1.5 29.0±1.4 42.5±1.6 9.7±0.9 
ZSize 69.9±1.5 30.6±1.5 42.4±1.6 10.7±1.0 
ZIC 70.6±1.4 31.5±1.5 44.1±1.6 11.0±1.0 
ZIC+Size 72.3±1.4 33.6±1.5 46.0±1.6 11.8±1.0 
ZDist 71.3±1.4 31.8±1.5 44.6±1.6 11.3±1.0 
ZDist+Size 73.3±1.4 33.8±1.5 46.1±1.6 12.2±1.0 
GSMA 55.3±1.6 19.1±1.2 30.7±1.5 7.5±0.8 
Fisher 47.8±1.6 17.9±1.2 22.9±1.3 4.2±0.6 
TPM 59.6±1.6 21.9±1.3 30.7±1.5 5.8±0.7 
 
 In a single replicate, there can be large differences for the p-value methods if 
the samples C and D are split or not, for instance in one replicate Fisher’s method 
gave a p-value of 1 at the disease locus when six studies were combined and a p-
value of 0.065 when the same families where arranged in four samples. For 
another replicate, the TPM method gave p-values of 0.0086 and 0.0659 at the 
disease locus, depending on the arrangement of families into subsamples. So, with 
the same data, the result can vary between significant to very far from significant. 
When a meta-analysis is classified as having a significant or not significant result 
at a certain level (again counting as significant a p-value below the significance 
level at any locus within 15 cM of the disease locus), the concordance between 
these results when arranging the families into six or four studies can be compared 
in a 2-by-2 table (with rows significant/not significant and columns 4/6 studies 
and one entry for each replicate). The Kappa coefficient of this concordance over 
the 1000 replicates is 1 for the weighted Z-scores, 0.84 for the TPM method, 0.71 
for Fisher’s method and 0.55 for GSMA on the 0.000022 level (on the 0.00074 
level the Kappa for GSMA is 0.64, the other methods have the same Kappas as 
before). As can be seen, the advantage of the Z-score combination methods is 





4.2.3 Type 1 error (significance level)  
The following presentation of the type 1 errors (tables 14 and 15) is intended to 
give only an indication of what can be expected with these meta-analysis methods. 
1000 simulations are generally not enough to estimate the type 1 error rate with 
appropriate precision. Thus, only values to a pointwise level of 0.01 are reported 
in detail (for the other levels less than 3 false positives occurred with each method 
in 1000 simulations). These are pointwise significance levels which imply a 
different type 1 error in a genome wide analysis with multiple correlated markers. 
According to the formula by Lander & Schork (1994) in the simulated setup (one 
90 cM chromosome) a pointwise α=0.01 corresponds to a chromosome wide 
α*=0.107, if an analysis with an infinitely dense marker map is assumed. Since 
this assumption is never fulfilled, the resulting correction from chromosome-wide 
to pointwise is too conservative. Thus the equivalent chromosome-wide level will 
in fact be considerably smaller.  
 The simulation of the single studies yields the chromosome-wide levels 
which correspond to the chosen pointwise levels in the chosen setup. For the 
single studies, chromosome wide false positive rates range between 0.022 and 
0.045 (table 14), for the meta-analyses with p-value methods 0.013 to 0.033 and 
for the Z-score combination methods 0.016 to 0.051 (table 15). Thus, within the 
limit of precision attainable by 1000 simulations, the type 1 error rates seem to be 
acceptable. The three p-value methods might be slightly more conservative than 
the Z-score combination methods.  
 
Table 14: False positive rates at a significance level of 0.01 (percentage of replicates with at least 
one p-value below 0.01 on an unlinked chromosome of length 90cM) for single studies. 
Study type Scenario 1:  multiplicative, GRR = 4 
Scenario 2:  
recessive, GRR = 4 
Scenario 3: 
multiplicative, GRR = 3.5 
A 3.4 2.5 4.2 
B 3.4 4.3 4.3 
C 3.6 4.3 4.1 
D 4.0 3.0 3.5 
C_1 2.2 3.9 2.7 
C_2 4.5 3.8 4.4 
D_1 4.0 2.7 4.5 





Table 15: False positive rates at a significance level of 0.01 (percentage of replicates with a p-
value below 0.01 for an unlinked chromosome of length 90cM) for combined analyses of four 
equally sized studies A-D (N=80 each) and of six studies A-D2 (N=80 or 40) of varying size. 
Four equally sized studies Six studies, varying size Method 
Scenario 1 Scenario 2 Scenario 3 Scenario 1 Scenario 2 Scenario 3 
Zunweighted 3.8 4.0 1.6 3.8 4.2 1.9 
ZSize - - - 3.8 4.0 1.6 
ZIC 4.4 4.8 2.7 4.6 4.7 2.9 
ZIC+Size - - - 4.6 5.0 2.6 
ZDist 5.1 5.0 3.2 4.9 5.0 3.2 
ZDist+Size - - - 5.1 5.0 3.2 
GSMA 2.2 2.6 1.3 2.6 3.3 1.9 
Fisher 2.1 2.9 3.2 2.6 1.7 2.3 






4.3 Discussion of the simulation study 
This simulation study presents the first comparison of methodology for meta-
analysis of genome wide linkage studies. In the simulated scenarios, under three 
different trait models with different genetic effect sizes, the p-value methods that 
have been applied so far in meta-analysis have consistently lower power than a 
direct combination of Z-scores. The unweighted combination of Z-scores gives 
9% to 15% (9% to 13%) more power than the p-value methods at the suggestive 
(significant) level when combining studies of the same sample size (table 10 for 
the multiplicative model with GRR of 4). In the normal situation that studies are 
of different size, a weighting with size raises the power of the Z-score method by 
2% to 3% compared to the unweighted method (table 12). And while this 
weighted method has the same power if the complete sample of families is split up 
into four or six studies, the p-value methods lose up to 9% power. And even more 
importantly, for a single replicate, the weighted Z-score combination gives the 
same result, while the p-value methods can give drastically different results on 
different partitions of the same data. In terms of power, Fisher seems to be the 
least robust, in terms of concordance of results, GSMA was the least robust when 
going from 4 to 6 studies with the same total sample.  
 When weighting with the additional information on marker map and 
information content as proposed here, the power increases by another 2% to 3%. 
Even though this gain is comparatively small, it is consistent across these 
simulations and as it comes at no additional cost, it should be exploited when the 
necessary information is available. The total difference in power between the best 
weighted Z-score combination and the p-value methods is 16% to 27% and 15% 
to 19% at the suggestive and significant level, respectively for the multiplicative 
model with GRR 4. For the recessive model it is 14% to 26% and for the 
multiplicative model with GRR 3.5 it is 13% to 15% at the suggestive level. The 
magnitude of possible gain in power depends on the specific situation, e.g. how 
much the studies differ in marker spacing and informativity. But in general, low 
information reduces power which can be interpreted as reducing the effective 
sample size of a study. 
 The false positive rates at a nominal 0.01 level were slightly higher for the Z-
score methods than for the p-value methods but all very close to the expected 




 The 15 cM microsatellite maps that were simulated represent gaps that are 
larger than the average marker spacing in genome scans, but it is common to have 
some gaps of at least this size (many published scans have about 10 cM average 
spacing, recent ones 3 to 5 cM but early ones even have 20 cM and all of these 
have to be included in a meta-analysis). And if the disease locus is in one of these 
gaps, the power to detect linkage is reduced substantially as could be seen in the 
individual studies. Situations with even worse constellations around the disease 
locus can occur by chance, e.g. when including candidate studies and sparser 
genome scans. 
 In the published applications of the p-value methods, study size and map 
information are usually ignored, even though appropriate weights could be 
integrated. However, in contrast to weighted Z-scores, the distribution of a 
weighted GSMA method under the null has to be derived by extensive 
simulations, which might be the reason why it is not performed in practice. For 
TPM and Fisher’s p-value combination, a weighting of studies, especially with 
sample size, but extensible to other weights as well, has been proposed (Good 
1955; Zaykin et al. 2002). It also relies on simulations under the null, since the 
exact distribution can be given only in special cases. Again, this improvement has 
not been widely adopted in applications of genetic epidemiology. For instance, 
Wu et al. (2002), and Badner & Gershon (2002a; 2002b) combine samples using 
modeifications of Fisher’s method without accounting for their very different 
sizes. Other extensions of weighting schemes, such as for differences in family 
structures, ascertainment, or general aspects of study quality can be developed. 
The weights proposed here are a first approach to address some of the most 
common differences between studies. The weighting by distance to the closest 
marker has the advantage of being independent of the observed genotype data and 
could be further refined by including a measure of the marker informativity such 
as polymorphism information content (PIC, Botstein et al. 1980), linkage 
information content (LIC, Guo and Elston 1999; Guo et al. 2002) or multipoint 
PIC value (MPIC, Rijsdijk and Sham 2002). 
 As noted above, it seems that the deviation under the alternative model is 
better captured by the Z-scores than by p-values, independent of the weighting. As 
a standard multipoint analysis often includes the calculation of NPL-scores, 




advantage of the Z-score method can also be utilized for genome scan data 
analyzed with any other linkage statistic, as Z-scores can be derived from p-values 
by the inverse of the normal distribution. This procedure was apparently 
introduced by Stouffer (1949, as cited by Hedges and Olkin 1985) and is also 
known as the inverse normal method. In general, caution must be applied when 
combining results from different test statistics - p-values as well as Z-scores - that 
have different underlying assumptions on the disease model.  
 In their article introducing TPM, Zaykin et al. (2002) compare their method 
with Fisher’s and the inverse normal method, among others. They directly 
simulate Z-scores under the null and under a shift alternative and investigate the 
situation where only some of the null hypotheses are false. This corresponds to 
genetic heterogeneity between studies, where only in some samples a disease gene 
segregates at the studied position. In this case, the TPM method performed best, 
and the power of Fisher’s procedure is higher than that of the inverse normal 
method. When all null hypotheses are false, i.e. the same disease locus is present 
in all studies, the inverse normal method has much higher power than TPM. For 
this simulation study, data was simulated under the same alternative for all 
studies, i.e. under the same disease model for all studies and thus similar results 
were obtained. The power of a meta-analysis compared to individual studies is 
highest for genes common to all investigated populations - for population specific 
genes the power necessarily drops. TPM accounts for possible genetic 
heterogeneity and therefore is less efficient when this is not present. Optimal 
methods for combining statistical tests depend on the alternative, especially 
whether all or just few of the null hypotheses are false. Some theoretical work can 
be found in a review article by Folks (1984), who investigates in which situations 
the inverse normal method, Fisher’s method or truncation methods are better. 
Further simulations for other realistic models of gene effects and heterogeneity 
within or between studies might be of interest, since a generalization of results 
always depends on the simulated model. The methodology investigated here was 
developed for studies that supposedly are homogeneous in this respect and 
simulations were done accordingly. The proposed weighting schemes correspond 
to fixed effects meta-analysis (Hedges and Olkin 1985). To account for genetic 
heterogeneity between studies, a random effects meta-analysis could be more 




identically by descent between affected sib pairs is the parameter of interest, the 
estimated numbers of sib pairs sharing 0, 1 or 2 alleles are necessary to calculate 
the appropriate between study variance of the parameter estimates (Gu et al. 
2001). However, most commonly used linkage software programs do not output 
the necessary statistics which greatly hampers such a random effects analysis. 
McQueen et al. (2006) recently proposed a bootstrap variance estimator for the 
average number of alleles shared identically by descent between affected sib pairs 
to be used in a random effects meta-analysis. Again, this relies on the availability 
of detailed data, here the family specific IBD estimates, which can be output by 
analysis programs such as Genehunter (Kruglyak et al. 1996) or Merlin (Abecasis 
et al. 2002), but are usually only available if the raw genotype data are also 
available. NPL scores and information content on the other hand are normal 
output of linkage programs for affected relative pairs and genome-wide NPL 
scores are usually also published. If conducting a meta-analysis with studies from 
very diverse populations it might be advisable to first combine all samples to find 
common genes and additionally analyze combinations of more closely related 











Identifying susceptibility loci for complex diseases such as asthma with the use of 
genome scans is a difficult task. One family study alone seldom yields statistically 
significant results for susceptibility genes of moderate effect. Higher power can be 
expected with a pooled linkage analysis of the combined raw data or a meta-
analysis of outcomes from different genome scans. Methodological problems are 
how to account for differences in population, ascertainment and family structure, 
phenotype definition and marker sets between studies. Weighting schemes for 
combining results from several genome scans are proposed. The GAW 12 asthma 
studies vary, partly extremly, in sample size, marker density and information 
content at each chromosomal location. For the combined analysis a simple sum or 
average of individual scores cannot account for these differences. To avoid 
confounding, different approaches of weighting the scores accordingly are 
investigated.  
 For a genome scan using multipoint linkage analysis of the pooled data sets, a 
common marker map is necessary, consisting of all markers genotyped in any one 
of the studies. The GAW 12 studies use at least partly different markers. From 
existing, publicly available marker maps the order and distances of all markers 
could not be determined unambiguously. Multipoint linkage analysis with a dense 
marker set has been reported as sensitive to misspecification of marker order and 
intermarker distance (Halpern and Whittemore 1999). Two different maps were 
constructed and used for multipoint linkage analysis to compare the results for 
discrepancies attributable to map differences.  
 
5.1 Data sets  
The data of GAW12 problem 1 consists of four genome scan and five 




Genetics of Asthma (CSGA, Xu et al. 2001), the Hutterites (Ober et al. 2000), 
Germany (Wjst et al. 1999), and Busselton in Australia (Daniels et al. 1996). The 
chromosome 5 data sets are from the Consortium on Asthma Genetics (COAG, 
Lonjou et al. 2000) and come from Southampton, Finland, Perth, Oxford and 
Freiburg as described by Palmer et al. (Palmer et al. 2001). The binary phenotype 
asthma was considered and all pedigrees with relevant affecteds for linkage 
analysis were used (see table 16), i.e. those with at least two affected genotyped 
members excluding parent-child pairs. Because of pedigree size limitations for 
multipoint linkage algorithms one pedigree (No.97) of the Oxford sample had to 
be divide into two families and the Hutterite pedigree was split into 14 families 
with at least two affected genotyped members by discarding most of the 
unaffected and untyped individuals.  
 











































































Families 225 88 97 52 43 30 14 14 4 
Relevant 
Affecteds 596 214 200 122 115 81 48 30 8 
Subjects 1492 517 415 399 235 222 174 70 20 
 
5.2 Methods 
5.2.1 Common Marker Map Construction 
A common marker map that contains all markers typed in any study was first 
constructed. This map is based on the Marshfield comprehensive human genetic 
linkage map (Broman et al. 1998) and was completed for markers without 
Marshfield distance by using genotype information of the GAW 12 studies. To 
assess sensitivity of the analysis method to marker order and intermarker 
distances, two maps that differed slightly in marker order and considerably in 
intermarker distances were assembled.  
 For each study marker name and order was provided. Marker distance (cM 
from p-ter) was only provided for the Hutterite and CSGA data sets. There were a 




The problems for the construction of the common map were: 
• Choice of a reference map. 
• Location assignment of markers used in a study but missing in the reference 
map. 
• Handling of different markers located at the same position. 
 Two different combined maps resulted, which are based on the same 
reference map, but with different handling of location assignment and same 
positions.  
 1. Reference map: The sex-averaged Marshfield comprehensive human 
genetic linkage map (http:// research.marshfieldclinic.org/genetics/, Broman et al. 
1998) was used as the reference map. For an entered list of markers corresponding 
distances are given, which is especially helpful for a large number of requested 
marker locations. The locations of typed markers in the Hutterite study correspond 
to the Marshfield map (rounded to one cM). If available, distances given by the 
CSGA or Hutterite study descriptions were used for markers missing in the 
Marshfield map. 
 2. Location assignment: Markers not appearing in the reference map were 
assigned a location in two different ways yielding slightly different maps. Given 
the GAW 12 data sets the order-based map utilizes only the order of markers and 
the data-based map additionally incorporates genotype information. For the order-
based map, missing markers were assigned a position corresponding to the 
provided order and equidistant to the flanking markers of the Marshfield map. For 
the data-based map, the location were assigned by two point and multipoint 
linkage analysis using the MLINK and LINKMAP options of LINKAGE (Lathrop 
et al. 1984) and the available genotype data. Based on the given marker order, 
linkage analyses with the closest typed markers and their Marshfield positions 
were performed. When several adjacent markers were missing, their relative 
positions were assigned by combining the results for these markers relative to 
each other and with neighboring markers of the Marshfield map.  
 3. Same position: For multipoint linkage analysis different markers have to be 
assigned distinct positions. In the Marshfield map markers separated by little or 
no genetic distance quite often have no recombination events in the CEPH 
families used and therefore are presented with the same position in arbitrary order. 




merged to one artificial marker in both maps. For the order-based map markers 
analyzed in the same study with the same position in the Marshfield map were set 
0.01 cM apart with their order as given in the study. For the data-based map they 
were tested for recombinations using two point linkage analysis. If no 
recombination was observed, the same procedure as in the order-based map was 
used. Otherwise markers were located by multipoint linkage analysis.  
 
5.2.2 Linkage analysis and weighting schemes for meta-analysis 
Multipoint linkage analysis of each study was performed with the ALLEGRO 
program (Gudbjartsson et al. 2000) an improved version of Genehunter (Kruglyak 
et al. 1996). For each pedigree the nonparametric linkage score statistic Zlr (using 
the exponential model as recommended by Kong and Cox 1997) was calculated at 
each position where a marker was typed in any of the studies. This score is based 
on IBD sharing in affected relative pairs. The pointwise scores were averaged 
using different study specific weights. Multipoint linkage analysis gives scores for 
every position along the genome and thus enables the combination of results from 
studies in which different marker sets were analyzed. However, when adding 
scores for each position across studies the differences in study size (number of 
affecteds) as well as the information content of each study at that position (or the 
distance to the next typed marker as an alternative measure of information 
content) should be taken into account so as not to bias the results towards the null. 
This can be done by using appropriate weights on the study scores. 
 The following weighted and standardized statistics were used (as defined in 
chapter 3): 
Z_1: equal weights 
Z_a: weights relative to the number of relevant affecteds included in the study 
Z_ic: weights relative to the number of relevant affecteds and to the information 
content of the considered locus in the specific study. As a measure for information 
content, the per-family information measure calculated in ALLEGRO was used.  
 Z_d2, Z_d10: weights relative to the number of relevant affecteds and an 
exponential function of the distance of this locus to markers typed in that study. 
The distance to the closest typed marker was calculated and used as argument of 




 These weighting schemes were compared with the Genome Search Meta-
Analysis Method (GSMA) proposed by Wise et al. (1999). As described in 
chapter 2, the chromosomes are split into bins of approximately equal length for 
GSMA. A bin width of approximately about 30 cM was used as proposed by the 
authors, resulting in 113 bins. For each study, the most significant result in each 
bin is recorded. The bins within one study are ranked accordingly. Then the ranks 
for each bin are summed across all studies. The exact distribution of the summed 
ranks under the null hypothesis of no susceptibility locus in a specific bin is given 
by the authors. The markers in the Busselton study are spread rather unevenly 
over the genome resulting in six bins containing no Busselton marker. One other 
bin contained no CSGA marker. Even increasing the bin size from the 
recommended 30 cM to 40 cM left some empty bins and created the additional 
problem on chromosomes 21 and 22 of using either one bin considerably larger or 
two bins considerably smaller than all other bins. Therefore 30 cM bins were used 
and only the ranks 1 to 53 and 60 to 113 were assigned to the Busselton data. 
Rank-sums and p-values for those bins were calculated as if there were only three 
studies. GSMA can only be used for the four genome scans and is not valid for the 
COAG data of the chromosome 5 candidate region. Application of GSMA to only 
a candidate region would violate the assumption of at least one marker in each bin 
and the distribution of the ranks of the candidate region alone would differ from 
their distribution among ranks in the whole genome. At GAW12 Wise presents an 
extension of GSMA to this situation where the null distribution is approximated 
by simulation (Wise 2001). 
 
5.3 Results 
5.3.1 Common Marker Map Construction 
For a total of about 800 markers the map locations could be assigned by the 
Marshfield linkage map. For about 100 markers the position was missing or more 
than one marker was at the same position in the Marshfield map.  
 The data-based and order-based maps contain 832 or 828 markers, 
respectively. Some markers merged into one marker in the order-based map could 
be assigned different positions in the data-based map. One marker (D3S11), 
allegedly located on chromosome 3 in one study, was positioned on chromosome 




agreement with several other physical and linkage maps. The data-based and 
order-based maps differ as follows:  
 1. Differences in location assignment: 47 markers were analyzed in at least 
one study, but were not contained in the Marshfield map or in the CSGA and 
Hutterite study description. These markers are located at different positions in the 
two constructed maps, the differences amounting to 1 cM for 13 markers, 2-4 cM 
for 16 markers, 5-10 cM for 14 markers and more than 10 cM (11-23 cM) for 4 
markers.  
 2. Differences for same positions: For a total set of 52 markers, two or more 
were located at the same position in the Marshfield map and genotyped in a single 
study. For 13 out of these 52 markers the positions in the two constructed maps 
were identical, since linkage analysis did not show any recombinations. For 39 
markers linkage analysis resulted in positions which differed from the original 
reference map. The localization of these 39 markers in the two constructed maps 
differs by 1 cM in 15 cases, by 2-4 cM in 13 cases, by 5-10 cM in 9 cases and 15 
cM in two cases. 
 To compare the results of the different maps, the analysis where Z-scores for 
each study were weighted relative to the number of relevant affecteds in the study 
and the information content calculated by ALLEGRO is considered. The results of 
this linkage analysis are presented as p-values yielded by the overall score statistic 
for each genome position. In general, differences in p-values for the two 
constructed maps were negligible, even where markers were differently 
positioned. There are a few regions for which small differences in p-values can be 
noted. Figure 4 shows the results for the region with the largest differences across 
the whole genome which was on chromosome 5 (130-156 cM). Figure 5 shows 





Figure 4: Multipoint linkage results using ALLEGRO for chromosome 5 based on the data-based 













































































































































































































Figure 5: Chromosome 5, region 130-156 cM. Presented are markers which are in this region for 





 The maximal difference is at position 137 cM with p-values 0.172 and 0.120 
for the data-based and order-based map, respectively. There were three positions 
(all within 3 cM) with differences in p-values greater than 0.04. Considering 
individual markers, the differences in p-values are maximal at marker D5S413 
(data-based map: 156 cM, p-value 0.287; order-based map: 150.01 cM, p-value 
0.157) and marker ADRB27 (data-based map: 155 cM, p-value 0.271; order-
based map: 149 cM, p-value 0.140). There were eight more markers in this region 
with differences over 0.05. 
 
5.3.2 Linkage analysis and weighting schemes for meta-analysis 
In the following the results of the combined analyses (figure 6, rows 1 – 6) are 
elucidated and compared to those of the single studies (figure 6, rows 7 – 10) to 
assess the weighting schemes. Here the data-based map was used as a common 
marker map. 
 GSMA: GSMA gives by design only one p-value per bin, none below 0.01. 






Figure 6: P-values along the whole genome for GSMA (row 1), the different combined scores 
Z_1, Z_a, Z_ic, Z_d2, Z_d10 (rows 2 - 6) and each genome wide study (rows 7 – 10); Note: 




Z_1: Of the combined scores, the unweighted Z_1 is closest to GSMA. 
Again, the p-values are far from significant and the minimal values are higher 
than those obtained for the single studies. However, the combined minimal p-
values are considerably smaller than those obtained by GSMA: below 0.01 at 
D5S421, 14cM away from the smallest value for the Hutterites, around D6S291, 
reflecting the German result supported by Busselton data, and at D12S327, 
combining the low values of German and Hutterite data, while the lowest values 
for the Hutterites 35cM away are leveled out by the other studies. 
 Z_a: When each study is weighted by the number of relevant affecteds 
slightly lower p-values were observed for the combined score at regions distinct 
from those indicated by Z_1. On chromosome 1 the low p-value of the German 
study of 0.009 corresponds to 0.002 in the combined analysis. The p-value 0.003 
of the CSGA study at the marker BETA corresponds to a p-value of 0.006 in the 
combined analysis, for D19S886 the p-value of 0.004 remains, while the peak on 
chromosome 12 is slightly shifted. Scores from the larger studies (CSGA, 
Germany) have considerably more weight. Thus small p-values from these studies 
are hardly influenced by other studies.  
 Z_ic: Use of the information content and the number of relevant affecteds 
gives a similar picture. Because of large differences in study size, the information 
content has a relatively small impact on the weights but close examination shows 
small differences between Z_ic and Z_a in p-values and peak locations in most 
regions. 
 Z_d10: The weighted score Z_d10 again shows much similarity to Z_a 
because the map density has only limited influence on the weights compared to 
the number of relevant affecteds per study. The agreement with Z_ic is even 
greater, reflecting the correspondence of data driven information content and 
theoretically chosen distance measure. However, p-values differ to some degree as 
for example Z_d10 gives a p-value below 0.01 for chromosome 9 which Z_a and 
Z_ic do not. 
 Z_d2: The results for the weighted score Z_d2 show much more variation. 
For markers untyped in a study the distance measure can lower the weights so that 
the combined score could essentially be based on a single or two smaller studies 




regions as indicated by Z_ic on chromosomes 1, 6, 9, 11, 19 . A suggestive result 
was reached at the marker BETA with a p-value of 0.0006. 
 For all methods the single p-values below 0.01 at D7S528 and D10S1248 for 
the German data, the distinct regions for German and Busselton data on 
chromosome 2, and the broad region indicated by Busselton data on chromosome 
22 are leveled out by the other studies. 
Figure 7 gives the combined results and individual weighting functions for all 
nine studies on chromosome 5. To investigate the direct impact of the weighting 
functions, the individual study scores Zlr need to be considered. In addition to the 
number of relevant affecteds, the information content or the distance function, 
respectively, calculated for each study and each marker yields the basis for the 
different weighting functions. Figure 7 displays the results for chromosome 5 for 
individual studies ordered in descending order of the number of relevant affecteds 
(see table 16). The first row shows the p-values for the indicated scores in the 
combined analysis. Among the remaining rows the first column shows the p-
values for the score Zlr for each individual study. The next columns, denoted by 
Z_ic, Z_d10, Z_d2 present the information content and the distance function, 
respectively, on a scale from 0 to 1 which yield the weighting functions for the 
corresponding score. 
 There is basically zero weight for the COAG studies outside the candidate 
region and very high weight within. All studies show high weights within the 
candidate region. The weights for Z_ic are smoother than the ones incorporating 
marker distance. Z_d2 displays gaps between markers with basically zero weights 
especially for the genome scan data. Z_d10 displays a reduction of weights in 
marker gaps rather similar to Z_ic, with higher weights than Z_ic at the typed 
markers. Z_d10 seems to give higher influence to a wider candidate region than 
Z_ic. Note that the information content and distances measures given in figure 7 
will be weighted again by the number of relevant affecteds such that their 

























































Figure 7: Combined and individual p-values, information content and distance measure for 
chromosome 5. Row 1: p-values for the indicated combined scores, remaining rows: a) Column 1: 
individual p-values of the single studies, column 2: information content, column 3&4 distance 
measure on which weighting functions for indicated scores are based (b) scale 0-1 for weights, 
omitted); Map distance omitted.  
b)
 
   





   
   
   
   
   
   
   
   




   
   
   
   
   




   
   
   
   
   
   
   








Differences in the linkage results based on the two constructed maps must be due 
to differently placed markers. Hence, for the most part of the genome differences 
were expected to be negligible. However, even around the differently placed 
markers, only a few differences could be found with a large effect on the absolute 
p-value. No regions with p-values under a screening level of 0.01 could be 
identified in this combined analysis. Thus in the current situation, none of the 
differences due to the marker maps are relevant for the interpretation of results. 
The largest differences can be seen for a candidate region on chromosome 5 
which was available for all data sets, including very small studies. Here, the 
differences in the marker maps are largest, since the Marshfield map, which 
contains only anonymous markers but not candidate genes, did not contain many 
markers of this region. 
 Overall are these asthma linkage results not sensitive in a relevant manner to 
the differences in the maps. Some large differences in p-values however indicate 
that map differences could change results for linkage regions between significant, 
suggestive and even non-significant. Previous studies have shown that serious 
map misspecification can result in appreciable effects on power and false positive 
rates of multipoint linkage analysis (Halpern and Whittemore 1999; Daw et al. 
2000). Since the availability of the human genome sequence as a physical map 
(Lander et al. 2001; Venter et al. 2001), marker order should not be a relevant 
problem for linkage analysis any more. Additionally, more precise linkage maps 
have also been published (Kong et al. 2002) and recently, improved databases 
which combine information from linkage and physical maps have been published 
(Kong et al. 2004; Duffy 2006).   
 This analysis, which does not specifically incorporate heterogeneity of data 
sets, shows that suggestive regions previously identified in single data sets could 
no longer be identified in a combined analysis. This might be due to shifts in 
estimated linkage location for individual data sets. A heterogeneity test for these 
genome scans has been done by another group at GAW 12 (Babron et al. 2001), 
and it was concluded, that the studies do not show significant evidence for 
heterogeneity. However, the authors caution that this test probably has low power 




 An important reason for the lack of significant results may be that the 
combined sample size is still too small to identify linkage to a complex trait such 
as asthma. The whole genome scans included only 340 families, for the 
chromosome 5 candidate region 567 families were available. Given the moderate 
power of ASP linkage analysis for complex diseases, this seems to be insufficient 
to reliably identify genes involved in asthma susceptibility. The only asthma 
susceptibility gene that was by now identified by positional cloning, the ADAM33 
gene on chromosome 20p13 (Van Eerdewegh et al. 2002), was identified in a 
genome scan of 460 families with a LOD score of 2.94 and through the help of 
subsequent association studies. Linkage to this genetic region has not been 
observed in most other asthma genome scans, including those in this meta-
analysis, which gives a minimum p-value of 0.01 on chromosome 20. In further 
association studies with larger sample sizes the effect of this gene appears smaller 
than in the initial report (especially in other populations, Blakey et al. 2005; 
Holgate et al. 2006), probably due to the expected bias in effect estimates from 
initial studies for loci identified through genome wide linkage analysis (Göring et 
al. 2001). A meta-analysis of association studies estimated the odd-ratio as 1.46 
for a SNP in this gene. Therefore, this linkage meta-analysis of only 340 ASP 
families did not have sufficient power to identify this gene and probably also had 
low power for other asthma susceptibility genes. 
 The different weighting schemes are based on both the number of relevant 
affecteds and on the corresponding information content or distance measure in 
each study. The number of relevant affecteds is highly variable between the 
studies (range 8-596) and thus has overwhelming effect on the weighting 
functions. Family structures varied also considerably between studies (affected sib 
pairs to extended pedigrees) and it should be remarked that more distant affected 
relative pairs (such as e.g. second cousins) offer greater power for linkage analysis 
than close relative pairs such as siblings. Additionally the power varies whether 
connecting relatives in the pedigree are genotyped or not and a useful definition of 
the relevant sample size in a linkage study depends also on the specific linkage 
test statistic used. Taking the number of affecteds without regard for the specific 
family structures as the weighting factor is a compromise which approximates the 
relevant sample size for linkage analysis in this setting (for a more thorough 




results of three large studies (CSGA, Germany and for chromosome 5 COAG 
Southampton) dominate the combined scores, except if the variation in marker 
density is given extreme weight. 
 The information content measure depends not only on the informativeness of 
the observed genotypes but also on the family structure and density of the typed 
markers so that the weighting scheme for Z_ic implicitly incorporates all these 
factors. The weighting according to the distance of typed markers for Z_d2 and 
Z_d10 on the other hand depends only on the used markers but not on the actual 
data. Z_d2 might be too variable for practical use and only sensible in 
combination with a smoothing procedure.  
 The GSMA method seems to have comparatively low power. To some extend 
this can be explained by the disregarding of differences in the size of the studies 
and the set of markers used. Still, compared to the unweighted combined scores 
GSMA p-values are higher. A problem with the GSMA method arises when typed 
markers are not evenly spaced and covering each chromosome with appropriate 
bins can become impossible. The extension of GSMA to include studies covering 
only candidate regions or to incorporate weights involves extensive analysis of 
simulated data which might be too time-consuming for multipoint analysis of 
larger families. GSMA is a true meta-analytic approach adequate for published 
data, but a combined analysis using as much information of the data as possible is 
preferable. 
 Pooling or meta-analysis is the only possibility to substantially increase the 
power of genome scans to identify genes of moderate effect. Results of the pooled 
analysis of the GAW 12 asthma data as a real data application of the proposed 
methods are promising although only one problem of pooled analysis, the use of 
different marker sets, was addressed. The appropriate weighting of family data 
with large differences in marker sets is necessary to avoid bias of the results 
towards the null. The proposed methods with weighting schemes, which do not 
require the raw data but only scores, measures for weights and a common map, 










Many epidemiological studies or genome scans for common diseases come up 
with large and well characterized samples. If a sufficient number of the recruited 
individuals are related and additionally DNA or genotype information is available, 
linkage analysis for several traits can be conducted. This was done in 12 
publications reporting genome scans in 28 separate samples for linkage with adult 
height (Deng et al. 2002; Geller et al. 2003; Hirschhorn et al. 2001; Perola et al. 
2001; Thompson et al. 1995; Wiltshire et al. 2002; Wu et al. 2003; Xu et al. 2002; 
Sale et al. 2005; Sammalisto et al. 2005; Willemsen et al. 2004; Liu et al. 2004). 
Most of these were performed in samples ascertained for specific diseases 
unrelated to body height such as diabetes (Wiltshire et al. 2002) or asthma (Wu et 
al. 2003) while a few were performed in population samples such as the 
Framingham Heart Study (Geller et al. 2003). 
 Adult height (stature) is a highly heritable trait, with heritability estimates 
around 0.8 (Preece 1996; Silventoinen et al. 2000; Silventoinen 2003; Xu et al. 
2002). In most of the published genome scans, heritability was also estimated 
from the study sample and reported values are between 0.69 (Perola et al. 2001) 
and 0.98 (Wu et al. 2003) (see table 19 below for the individual estimates). Height 
is a trait that follows a normal distribution in the whole population, as noted by 
Pearson and Lee already 100 years ago (Pearson and Lee 1903), who explained 
how this can be the result of many genes, each with a small, additive effect 
independent of the others, termed a polygenic model. But more recent segregation 
analyses showed also evidence for major genes on top of the purely polygenic 
inheritance (Ginsburg et al. 1998; Xu et al. 2002).  
 Many candidate genes for stature and growth-related traits have been 
proposed and studied for association. These include genes of the growth hormone-
IGF-system (e.g. GH1, GHR, GHRHR, GHSR, IGF-1, IR, STAT5b), genes 




in pituitary development (e.g. POU1F1, PROP1, LHX3, LHX4, HESX1), and 
several others (Kant et al. 2003, see also table 25 in the discussion). Studies 
relating to these candidate genes and monogenic forms of growth disorders have 
been extensively reviewed (e.g. by Palmert and Hirschhorn 2003). 
 Additionally, the genetic analysis of variation in stature can be supplemented 
by the study of genetic syndromes which include short or tall stature among their 
cardinal features, such as Noonan Syndrome (OMIM 163950), Prader-Willi 
Syndrome (OMIM 176270) and many others. In some cases, genes responsible for 
these syndromes might also have alleles which influence normal growth variation 
or the whole syndrome is caused by microdeletions which include dozens of genes 
(e.g. Prader-Willi Syndrome), just one of which might be involved in growth 
regulation. Similarly, the short stature seen in Léri-Weill dyschondrosteosis 
(LWD, OMIM 127300) and Ullrich-Turner Syndrome is caused by 
haploinsufficiency due to heterozygous deletions or mutations of the SHOX gene 
or its regulatory regions (Attie 2000; Benito-Sanz et al. 2005; Rao et al. 1997). 
Such mutations or deletions in the SHOX gene seem to be responsible for a 
fraction of patients with idiopathic short stature as well. 
 This meta-analysis of linkage genome scans for adult height was conceived 
when analysing a genome scan of the Framingham Heart Study for this phenotype 
and noting remarkable overlapping linakge peaks with some of the previously 
published genome scans for height. However, there were also other scans which 
had identified different regions that did not seem to be replicated by our own 
results. Therfore a meta-analysis of all available genome scans for the phenotype 
stature seemed highly desirable to exactly quantify the evidence for linkage in 
these regions.  
 In this chapter, the linkage scan for height in the Framingham Heart Study 
sample is presented first, followed by the meta-analysis of genome scans for adult 
height. 
 
6.1 Framingham Heart Study genome scan for height  
The Framingham Heart Study is a large epidemiological cohort study, started to 
investigate risk factors for coronary disease. The sampling approach for the 
original cohort, which was recruited on a household basis, i.e. all household 




participants which where extended for the Framingham family study with an 
offspring cohort in 1971. 
 GAW13 provided genetic and anthropometrical data from 330 general 
pedigrees of the Framingham Heart Study. In this sample, the genetics of height 
were studied using a two-stage approach, which ensures that all individuals can be 
analyzed together. First, regression models for the phenotypes were built to obtain 
a single adjusted trait value for each individual. At the second stage, a linkage 
analysis incorporating all genotyped individuals was performed. 
 
6.1.1 Methods 
6.1.1.1 Study group 
The individuals from the Framingham Heart Study were recruited at two time 
points (the original cohort in 1948 and the offspring cohort in 1971) from the 
general population excluding those with cardiovascular diseases, heart attack, or 
stroke. Almost all participants were of Caucasian origin. From the 330 largest 
pedigrees with 4692 members, DNA was available for 1702 individuals, who 
were genotyped for 401 markers on the 22 autosomes. The positions of the 
markers were from the Marshfield map 
(http://research.marshfieldclinic.org/genetics, Broman et al. 1998),  using the sex-
averaged positions converted to the Haldane mapping function. Phenotypic 
information is provided for 2885 persons (1213 from the original cohort). Detailed 
information about the Framingham Heart Study is given at 
http://www.nhlbi.nih.gov/about/framingham/index.html. 
 
6.1.1.2 Condensation and trimming of pedigrees 
The given pedigrees had to be condensed and trimmed to enable efficient 
multipoint linkage analysis with Merlin (Abecasis et al. 2002). Condensation was 
done without losing linkage information since only untyped individuals were 
discarded. Here, ungenotyped persons without children and untyped founders with 
only one child were removed, since they are not informative for linkage. After this 
step, four families were removed because they had no informative relationship left 
and four families fell into two unrelated branches. Finally, 14 families, which 
were still too large to allow some of the planned analyses, were trimmed by 




resulted in a total of 346 pedigrees with 2656 individuals used in all analyses. The 
pedigree size ranged from four to eighteen individuals in two to four generations. 
 
6.1.1.3 Phenotype definition 
The phenotype height was investigated as the maximum of the available height 
measurements over the age of 18 years. Regression models for height were built 
for each sex in the original and the offspring cohort separately, adjusted for age at 
first examination to account for the different years of birth. The model for the ith 
individual is: 
 
with µ - overall mean, ai - age at first examination and ei - residual. The 
standardized residuals are approximately normally distributed and were taken as 
height variables in the linkage analyses. 
 
6.1.1.4 Linkage analysis methods 
Multipoint linkage analyses for the height phenotype were done with the variance 
components (VC) models implemented in Merlin (Abecasis et al. 2002) and 
SOLAR (Almasy and Blangero 1998) and the inverse regression method (Sham et 
al. 2002) implemented in Merlin-Regress.  
 Variance components methods model the phenotypic variance which is 
explained by the estimated identity-by-descent sharing at a chromosomal position. 
Merlin (Regress and VC) calculates exact IBD sharing probabilities using the 
Lander-Green algorithm with sparse gene flow trees and can handle pedigrees up 
to about 20 individuals for multipoint analysis (Abecasis et al. 2002). On the other 
hand, SOLAR estimates multipoint IBD sharing probabilities with a 
generalization of the Fulker method (Fulker et al. 1995; Almasy and Blangero 
1998) and has no restriction on the pedigree size. 
 
6.1.2 Results 
For chromosomes 6p, 6q, 9, 12, 14, 18 and 22, LOD scores greater than 1 for 
adult height were obtained with at least one analysis method. The strongest 





LOD score of 2.45 for Merlin-Regress and a 1-LOD support interval spanning 
from 190 to 204 cM. The variance components methods gave LOD scores of 1.83 
and 1.67 at the same position (Figure 8). Table 21 gives all LOD scores greater 
than 1. The heritability of maximum height was estimated by the VC methods as 
0.8. 
 
Table 17: Multipoint LOD Scores >1 for adult height with different methods. 
 
 
Figure 8: Multipoint LOD scores for height from SOLAR, Merlin-VC and Merlin-Regress for the 
22 autosomes. Analysis method: SOLAR (black line), Merlin-VC (red line), Merlin-Regress (blue 
line). For ease of presentation, negative LOD scores from Merlin-Regress were set to 0. Positions 




Chromosome  Marker 
Peak Position 
(cM) SOLAR Merlin-VC Merlin-Regress 
6 D6S2434 23-28 1.24 1.34 1.36 
6 GATA184A08 159-162 1.19 1.06 1.14 
6 D6S503 200-201 1.83 1.67 2.45 
9 D9S319 60-61 1.22 1.15 1.56 
12 D12S398 70-77 0.48 1.33 1.70 
14 D14S742 5-11 1.27 0.80 1.02 
14 D14S1426 137 1.35 1.49 1.58 
18 D18S1364 111 1.54 1.44 1.73 
































































6.1.3 Discussion  
A linkage genome scan for the quantitative phenotype adult height was performed 
in the extended pedigrees of the Framingham Heart Study. Analyses were 
conducted using two variance components approaches (SOLAR and Merlin-VC) 
and one regression method (Merlin-Regress), which gave very similar results. 
Even though the power of linkage analysis was substantially reduced since for 
many founders no DNA was available, this population-based and unselected 
sample has been a good example for the successful identification of linked 
regions. The results indicate that for moderately to highly heritable traits the 
analysis of phenotypically well characterized but unselected and rather large 
samples of extended pedigrees is promising. Other such large epidemiological 
cohort studies, where many covariables are carefully collected, can be valuable 
and efficient tools in studying the genes and interactions between genes and 
environmental factors in common complex diseases. 
 A first comparison of the linkage results in this study with previous genome 
scans for the same phenotype identified several regions of potentially overlapping 
linkage findings. In particular, on chromosome 6q there was a broad peak with a 
maximum LOD of 2.45 at 201 cM. Interestingly, Hirschhorn et al. (2001) and Xu 
et al. (2002) reported LODs of 3.85 at 159 cM and 3.06 at 155 cM, respectively. 
In this region a LOD score of 1.19 was obtained and it remains unclear if the 
maximum LOD scores on 6q result from the same locus. Substantial corroborative 
evidence exists also from Hirschhorn et al. (2001), Xu et al. (2002) and Perola et 
al. (2001) for the regions on chromosomes 6p, 9, 12, 14, 18 and 22 (see table 22).  
 
Table 18: Multipoint LOD scores for adult height in different scans. 








Perola et al. 
2001 
6p 0-30 1.36 <1 1.08 1.4 
6q 155-200 2.45 3.06 3.85 0 
9 42-66 1.53 2.09 2.01 0.15 
12 56-80 1.55 1.86 3.35 0.82 
14 11-47 1.02 <0.8 <1 1.67 
18 72-116 1.73 <0.5 1.77 1.71 
22 0-27 1.28 <0.8 1.95 0.54 
Upper limits for the LOD scores <1 from Hirschhorn et al. (2001) and Xu et al. (2002) were 




 However, there was no overlap with the putative linkage regions reported by 
Thompson et al. (1995) and Wiltshire et al. (2002). Deng et al. (2002) reported a 
LOD score of about 1 on chromosome 18 at 75 cM. When comparing the results 
from these genome scans, differences between the studies have to be considered. 
Whilst all but one study investigated individuals of Caucasian origin (Thompson 
et al. (1995) analyzed Pima Indians), differences in sampling, sample size, 
pedigree structure and marker sets were more pronounced. 
 To exactly evaluate the combined evidence for linkage to the phenotype adult 
stature in these regions and throughout the genome, a meta-analysis of all 
published genome scans was therefore conducted. 
 
6.2 Data sets for meta-analysis 
For this meta-analysis, all published linkage genome scans up to August 2004 for 
the phenotype adult height were intended to be included (Deng et al. 2002; Geller 
et al. 2003; Hirschhorn et al. 2001; Perola et al. 2001; Thompson et al. 1995; 
Wiltshire et al. 2002; Wu et al. 2003; Xu et al. 2002). The 8 identified studies 
reporting linkage genome scans for adult height vary in several aspects of study 
design. An overview of important points is given in table 17. The first molecular 
genetic study of adult height was published in 1995, the others between 2001 and 
2003. Most studies included Caucasian families, from different countries in 
Europe and North America, one used Pima Indians and one had subsamples of 
African American, Mexican American and Asian ethnicity. Five studies used a 
single sample each and 3 studies combined four to eight subsamples. The 
collection includes two cohort studies of families not ascertained for a specific 
phenotype and 20 studies that recruited for phenotypes such as hypertension, 
asthma or diabetes. Family structures that were recruited also differ substantially 
between studies from sib pairs to 3-4 generation pedigrees and average family 











Country or Region 
No of separate 
samples 
Phenotype for which 
studies were ascertained 
Thompson 1995 Pima Indians 1 Cohort study, no specific 
phenotype 
Hirschhorn 2001 Finland, Sweden, 
Canada (Quebec) 
4 Diabetes 2, coronary heart 
disease 
Perola 2001 Finland 5 Hypertension, obesity, 
osteoarthritis, migraine, 
familial hyperlipidemia 
Wiltshire 2002 UK 1 Diabetes 2 
Xu 2002 Netherlands 1 Asthma 
Deng 2002 US whites 1 Osteoporosis, obesity 
Geller & 
Dempfle 
2003 US whites 1 Cohort study, no specific 
phenotype 
Wu 2003 European American, 
African American, 
Mexican American, 
Japan and China 
8 Hypertension 
 
6.2.1 Study identification and data collection 
All published linkage genome scans up to August 2004 for the phenotype adult 
height were intended to be included in this meta-analysis. Segregation analyses 
and association studies or mutation screens of candidate genes are not included. 
Relevant studies were identified through searches of PubMed 
(http://www.ncbi.nlm.nih.gov) using different combinations of the search terms 
“genome”, “scan” or “screen”, “height” or “stature” and “linkage”. Abstracts of 
the PubMed search results were read and yielded six eligible publications (Perola 
et al. 2001; Hirschhorn et al. 2001; Wiltshire et al. 2002; Xu et al. 2002; Deng et 
al. 2002; Wu et al. 2003). Additionally, the identified papers and their reference 
lists were searched for other publications. This resulted in the identification of the 
paper by Thompson et al. (1995) where the title, abstract and key words do not 
reveal that a genome scan was done. The analysis of the Framingham Heart Study 
genome scan for the phenotype height was done in the context of the Genetic 
Analysis Workshop 13 (GAW13) and was published in December 2003 (Geller et 
al. 2003). The four studies published after August 2004 (Liu et al. 2004; Sale et al. 
2005; Sammalisto et al. 2005; Willemsen et al. 2004) were not included. The 
study of Liu et al. (2004) was performed in an extended sample of that used by 




 For a meta-analysis of genome scans, it is necessary to have the results of 
each study at corresponding locations along the whole genome available to 
combine them appropriately. These could be results from common markers that 
were genotyped in several studies or at evenly distributed positions, e.g. every 
cM. Publications of genome scan studies usually do not include the results in such 
detail, but report only the markers or positions with the most interesting results 
exactly and include all other results in a figure. Therefore the authors of all 
published studies were contacted and asked for the detailed results, including the 
names and positions of all genotyped markers and LOD scores or other linkage 
statistics for all available positions. Details of the study design that were not 
sufficiently clear from the publications were also requested, such as information 
on family structures and numbers of genotyped and phenotyped individuals. The 
data used for the meta-analysis were only a more detailed version of the already 
published summary statistics (mostly LOD scores) and not any individual data 
such as genotypes. 
 Six of the contacted seven authors agreed to supply the necessary detailed 
results for the meta-analysis. The authors of Thompson et al. (1995) refused to 
make their results available, even after an intervention of the journal’s editor. The 
American Journal of Medical Genetics where this study was published does not 
currently have a policy on authors’ obligations to make data available to other 
interested scientists. Thompson et al. (1995) report in their publication only 
results on chromosome 20, where some markers showed significant p-values. No 
data for the other chromosomes are given. Therefore the results for chromosome 
20 could not be included in the meta-analysis as this would bias the combined 
conclusions (publication bias).  
 
6.2.2 Description of published genome scans 
In the following, the design and important results of each of the separate genome 
scans are briefly presented. An overview of design and statistical methods of all 
scans is given in tables 18 and 19 for convenient comparison of important features 






























Perola 580 Sib pairs 2.5 247 530 
Wiltshire 1377 Sibships 2.4 573 418 
Xu 962 2-3 Generations 4.8 200 366 
Deng 630 Larger pedigrees 11.9 53 380 
Geller & 
Dempfle 1702 2-3 Generations 7.7 346 401 
Wu 6752 Sibships / nuclear families 2.7 2508 372 
 
 
Table 21: Overview of statistical analyses in published genome scans for height (NR: not 
reported, VC: Variance components, SDS: Standard deviation scores). 
First 
author 










Thompson NR NR NR NR Haseman-
Elston 
SAGE 
Hirschhorn SDS Age  Sex, 
study 
group 
0.7 - 0.95 VC Genehunter2 
Perola Square root, 
SDS 
Age  Sex, 
study 
group 
0.69 VC SOLAR 





Sex 0.89 VC Genehunter2 
Xu SDS Age  Sex 0.78 VC SOLAR 
Deng - Age  Sex 0.73 VC SOLAR 
Geller & 
Dempfle 
SDS Age  Sex, 
cohort 
0.80 VC SOLAR / 
Merlin 
Wu SDS Age  Sex, 
study 
group 









As an overview of the important results of each scan, the different regions 
highlighted together with the obtained LOD scores is given in table 20. For a 
better comparison of these individual results and easier assessment of their 
concordance (or lack thereof), the LOD scores along the genome are plotted in 
figure 11 (together with the results of the meta-analysis), see below after the 
description of the individual scans (pages 98-105). 
 
Table 22: Results of the individual scans as published. The two highest LOD scores and 
corresponding genetic region (approximate cM position according to the publication) are given. 
NR = not reported, ‘-‘ in the sample column denotes publications with just one sample. 
Region of highest 
LOD score 
Region of second 











20 34-40 NR - - 
Hirschhorn Botnia 3.85 6 159 2.69 17 66 
Hirschhorn Finland 3.56 13 80 3.35 12 56 
Hirschhorn Sweden 3.40 7 150 1.95 22 0 
Hirschhorn Sanguenay-Lac-St.-Jean 1.35 17 40 1.26 4 13 
Perola combined 2.91 7 164 2.61 9 159
Wiltshire - 3.17 3 9 2.26 7 103
Xu - 3.06 6 150 2.09 9 50 
Deng - 2.14 5 144 1.95 X 10 
Geller & 
Dempfle - 1.83 6 200 1.54 18 111
Wu European Americans 3.67 14 67 2.66 6 78 
Wu African Americans 2.25 1 136 NR - - 
Wu Mexican Americans NR - - NR - - 
Wu Asians 1.60 14 67 1.48 5 134
 
Thompson et al. scan (1995) 
The Thompson et al. (1995) scan used a sample from a cohort study on the 
genetics of type 2 diabetes and obesity in Pima Indians from Arizona (USA), but 
included only non-diabetics in this analysis. Sib pairs and their parents from 226 
families were genotyped for 160 markers and analyzed for the phenotype stature 




chromosome 20 (D20S66, D200S98 and D20S118; 34 to 40 cM) showed 
evidence for linkage to stature with nominal p-values of 0.0001 to 0.0003. 
D20S118 also showed evidence for linkage to leg length with a nominal p-value 
of 0.0002. A mutation screen of a candidate gene in this region, Bone 
morphogenetic protein 2 (BMP2) in 40 of the tallest and shortest individuals of 
the study group revealed one SNP, which was not associated with height in these 
40 subjects. They concluded that other genetic variation in the region must be 
responsible for the observed linkage. 
 
Hirschhorn et al. scan (2001) 
Hirschhorn et al. (2001) used four different samples for their linkage analysis of 
height, a sample from the Botnia region in Finland, one from other parts of 
Finland and one from Southern Sweden, all with probands ascertained for type 2 
diabetes, and one sample from the Saguenay-Lac-St.-Jean region in Canada with 
probands with either type 2 diabetes or coronary heart disease. The four samples 
were genotyped separately for different marker panels and the linkage analyses 
were also done separately using the variance components method implemented in 
Genehunter 2 (Pratt et al. 2000). This resulted in four genomic regions with LOD 
scores >3.3 on chromosomes 6, 7, 12 and 13 in different samples. In none of these 
regions, another sample reached LOD scores > 1 to support the respective result. 
On the other hand, there were another five regions (on chromosomes 4, 11, 17, 18 
and 22) in which two samples each showed LOD scores between 1.35 and 2.69. A 
combined analysis of all four scans was done, using GSMA (Wise et al. 1999) 
which showed no genome-wide significant result, with the highest ranked bin 
overlapping the chromosome 6 region that was significant in the Botnia scan. This 
shows the difficulty in judging whether a region with one genome-wide 
significant result in a single scan and no replication of this in several other scans 
or rather e.g. two suggestive results in independent scans represent on the whole 
more statistical evidence for linkage. Only a quantitative meta-analysis, which 





Perola et al. scan (2001) 
Perola et al. (2001) report a combined analysis of height in five samples from 
Finland, ascertained for osteoarthritis, familial combined hyperlipidemia, 
hypertension, obesity and migraine. Here, genotyping was done separately with 
only slightly different marker panels, but then the individual genotype and 
phenotype data were analyzed as one sample, again using variance components 
linkage analysis. Separate analyses of the samples were also done, but no detailed 
results were reported and could also not be obtained from the authors. The 
maximum LOD score on chromosome 7 is carried mostly by one sample and 
overlaps with the chromosome 7 peak in the Swedish sample by Hirschhorn et al. 
(2001). 
 
Wiltshire et al. scan (2002) 
Whiltshire et al. (2002) conducted a linkage analysis for stature in a single, large 
British/Irish sample that had been recruited for type 2 diabetes, including 573 
sibships. The region of their highest LOD score on chromosome 3 is not 
highlighted in any of the other scans and their region on chromosome 7 is about 
60 cM from the peaks on chromosome 7 obtained by Perola et al. (2001) and 
Hirschhorn et al. (2001). Indeed, at the Perola and Hirschhorn region (around 150-
165 cM), Wiltshire at al. (2002) have a LOD score of 0. 
 
Xu et al. scan (2002) 
Xu et al. (2002) used a sample of 200 Dutch families ascertained through a 
proband with asthma to first perform a detailed segregation analysis of adult 
height followed by a genome wide linkage analysis. Heritability estimates were 
around 0.8 for most relative pairs used to calculate correlations, well in 
accordance with estimates reported elsewhere (Preece 1996; Silventoinen et al. 
2000; Silventoinen 2003). There was also significant evidence of assortative 
mating for height, with a spouse correlation of 0.16. The segregation analysis 
gave the best fit for a mixed-recessive model, i.e. a model with a major recessive 
gene and residual polygenic effect, while a purely polygenic model fit the data 
significantly worse. The hypothetical recessive gene would explain 38% of the 




 In the linkage analysis, the highest LOD (3.06) was obtained on chromosome 
6, very close to the peak in the Botnia sample by Hirschhorn et al. (2001). Close 
to the second highest LOD (2.09 on chromosome 9) was another Botnia peak with 
a LOD of 2.01. The third highest peak (1.86 on chromosome 12) overlaps with yet 
another peak from the Hirschhorn et al. (2001) study in the Finland sample (LOD 
of 3.35). 
 
Deng et al. scan (2002) 
Deng et al. (2002) searched for linkage to adult height in a sample of white 
Americans of European descent which had been collected for a study on the 
genetics of osteoporosis. Each of the 53 extended pedigrees contained a proband 
with low bone mineral density (lowest 10 percentiles of population), which is 
correlated with height (r²=0.12 in this sample, sex-adjusted), leading to 
significantly smaller heights in probands (sex- and age-adjusted difference of 8 
cm). This ascertainment was accounted for in the variance components linkage 
analysis.  
 Deng et al. (2002) obtained their highest LOD score of 2.14 on chromosome 
5 (close to a region with a LOD score of 1.48 in the Asian sample of Wu et al. 
(2003)), and a two-point LOD score of 1.95 on the X chromosome, which was not 
analyzed by the other studies and thus not included in this meta-analysis. 
 
Wu et al. scan (2003) 
Wu et al. (2003) analyzed the by far largest collection of more than 6700 
individuals in more than 2500 families from eight different studies in four ethnic 
groups. These had all been recruited to study the genetics of blood pressure and 
hypertension. The genotyping was done for all eight samples together and with 
the same markers. The primary analysis as reported in the publication was done 
separately for the eight samples, but a combined analysis was also carried out. For 
the meta-analysis, the results of the separate analyses are used.  
 Two regions had elevated LOD scores in both European Americans and 
Asians (LODs of 3.67 and 1.6 on chromosome 14 and LODs of 2.26 and 1.48 on 
chromosome 5). On chromosome 6, a LOD of 2.66 was reached in the European 
American sample, but this is about 70 cM away from the LOD score peaks of Xu 




The strongest support for linkage in the combined analysis was found on 
chromosome 7 (LOD 2.46), which did not stand out in any of the eight individual 
analyses, but is in the same region as the chromosome 7 peaks of Hirschhorn et al. 
(2001, Swedish sample) and Perola et al. (2001). 
 
6.3 Meta-analysis methods 
6.3.1 Available Data 
From the published studies, VC LOD scores (from SOLAR or Genehunter) along 
the 22 autosomes were available, either at regular intervals, e.g. every 1 cM or at 
the genotyped markers and at certain positions between them. Additionally, the 
names and assumed positions of the genotyped markers were provided. Only the 
study by Deng et al. (2002) reported results for the X-chromosome, all other 
studies did not perform linkage analysis for this chromosome and therefore it was 
not included in the meta-analysis. For all studies, the sample size (usually number 
of phenotyped and number of genotyped subjects) and in more or less detail, the 
distribution of the sample in families (number of families, family structure such as 
sib pairs with or without parents) was given. For only two studies, additional data 
was obtained such as the Genehunter information content at the same positions as 
the LOD scores, but for almost all of the studies this was not available and thus 
could not be used in this meta-analysis. 
 The VC LOD score, which is the difference in log10 likelihoods between the 
restricted and unrestricted variance components models is equivalent to a regular 
parametric LOD score, i.e. twice the difference in loge likelihoods between the 
restricted and unrestricted models yields a test statistic that is asymptotically 
distributed as a ½:½ mixture of a χ2 variable with one degree of freedom and a 
point mass at zero (Self and Liang 1987; Almasy and Blangero 1998). Thus VC 
LODs can easily be converted to p-values or standard normal Z scores (and vice 
versa), which can then be used in a meta-analysis. 
 The VC LOD score is a measure of significance and not an effect estimate. 
Relevant effect size measures for variance components linkage analysis would be 
the (additive) genetic variance component or equivalently the locus-specific 
heritability (h²). With these and the respective variance estimates, a fixed or 
random effects meta-analysis would be possible. Most genetic analysis programs 




Blangero 1998)) do not routinely provide these estimates, and they were not 
available for this meta-analysis. The program Merlin-Regress (Abecasis et al. 
2002) on the other hand, which implements a regression approach to quantitative 
trait linkage analysis (Sham et al. 2002), normally provides estimates of the locus-
specific heritability and its standard error in the detailed output.  
 
6.3.2 Common marker map 
In a meta-analysis of linkage studies, it is essential that linkage information of the 
same genetic location is combined over studies. This can easily be achieved if the 
same markers are analyzed in all studies, but becomes more difficult if the 
markers differ between studies. Even for markers that are common to more than 
one study, the assumed positions of markers for the analysis often differs, either 
through use of different marker maps, such as the Marshfield (http:// 
research.marshfieldclinic.org/genetics/, Broman et al. 1998) and deCode maps 
(Kong et al. 2002), or because the position of the most proximal genotyped 
marker of each chromosome is arbitrarily designated as 0 cM. In this case, 
distances between markers may be equal across studies, but absolute positions in 
cM are not. Therefore a locus designated at the same cM position in different 
scans does not necessarily specify the same genetic location. This has to be 
corrected by constructing a consensus map, which includes unique cM positions 
for all markers genotyped in any study and subsequently repositioning all results 
(LOD scores) to this map. For the height meta-analysis, the Marshfield map 
(Broman et al. 1998) was chosen as the basis of this consensus map, because 
many of the individual studies had already used this map in their analysis (in 
several cases with the first genotyped marker on each chromosome given the 
position 0 cM). Of the total 1558 different markers in all studies, 1467 were 
included in the Marshfield map; only 91 are missing from the Marshfield map. 
The marker order was consistent with that used in the individual studies. Markers 
that were not included in the Marshfield map were placed according to their 
relative position assumed in the single studies, i.e. between the same flanking 
markers and at the same relative distance to them. The reported LOD scores were 
now designated new positions according to the positions of the corresponding 




the same marker are therefore assigned the same position and will then be 
combined in the meta-analysis. 
 Since the positions of the first and last marker on each chromosome differ 
quite a lot between studies, results of each study were only included 2 cM beyond 
the first and last genotyped marker. 
 
6.3.3 Combination of linkage results  
The only data available from all studies were variance components LOD scores, 
which are measures of significance (essentially a function of the likelihood ratio 
test statistic and thus equivalent to p-values) and no measures of effect size and 
corresponding standard errors could be obtained. Therefore only a meta-analysis 
method that uses p-values could be applied such as Fisher’s p-value combination 
method. As Elston (1991) observes, Fisher’s method is asymptotically optimal 
among essentially all methods to combine significance levels of independent tests. 
VC LOD scores were first transformed to p-values (via the χ2 distribution), these 
were combined and the resulting p-value was back-transformed to a LOD score. 
This transformation to LOD scores is mainly done for ease of comparison with the 
results of the single studies. A slight modification is necessary since VC methods 
do not give negative LOD scores, even if allele sharing between affecteds is less 
than expected, but rather truncate the LOD score space at zero. So LOD scores of 
0 are biased and should therefore not be assigned a p-value of 0.5 (as would be the 
case in parametric linkage analysis). Province (2001) pointed this out and 




≈  in a meta-
analysis as a way to avoid a bias in the combined result. This was used in the 
current meta-analysis.  
 There is no clear consensus in the literature, whether Fisher’s method 
sufficiently accounts for different sample sizes of the combined studies (see 
Hedges and Olkin 1985, p. 38). The p-value results both from the observed effect 
size and the sample size. Thus, for a given effect size, the p-value will reflect the 
sample size, but since effect sizes are not expected to be constant across studies 
(not exactly the same IBD sharing at all locations in different samples), the p-
value is no longer proportional to sample size. Weights, which could reflect 




the p-values with the respective study weights (Good 1955). However, the 
distribution of the weighted test statistic is no longer a simple χ2 distribution and 
is only known if the weights are distinct. Additionally, an optimal choice of 
weights has only been evaluated for special designs (Hedges and Olkin 1985). 
 The inverse normal method (Stouffer et al. 1949) on the other hand can easily 
be used unweighted or weighted with the relevant sample size for each study. For 
the weighted form, p-values (derived from LOD scores with Province’s bias 
correction) were transformed to corresponding standard normally distributed Z-
scores and these were weighted by study size and combined to a standardized Z-
score which was back-transformed to a LOD score. These are defined as follows: 
let k be the number of studies, and nj (j=1, …, k) be the relevant sample size of 
study j (as defined in the next section). Let, pj(t) (j=1, …, k) be the p-value of 
study j at position t (in cM) and Zj(t) = Φ-1[pj(t)] be the standard normal quantile 






















)(  . 
For comparison, results of three different meta-analyses are therefore presented, 
using Fisher’s method, the unweighted inverse normal method and a weighted 
inverse normal method.  
 
6.3.4 Relevant sample size 
Weighting of the linkage results should be proportional to the sample size. In 
contrast to other types of studies, where each individual contributes the same 
amount of information and therefore the relevant sample size is just the number of 
individuals, this is not necessarily the case in a linkage study. The basic unit of 
information for linkage would be one informative meiosis (where a recombination 
or non-recombination is counted), so only non-founders in a pedigree can contain 
linkage information and while founders do not contain linkage information 
themselves, they can (through determination of phase) enhance the information of 
their children. Depending on the linkage test statistic used, an individual in a 




unaffected offspring can also be counted as recombinant or non-recombinant in 
parametric linkage analysis (depending on the underlying penetrance model) but 
do not usually contribute to an affected sib-pair analysis (if parents are not typed, 
unaffected siblings may be used to improve IBD estimation). If the disease model 
is unknown, it is not known which meioses (dependent on phenotypes, i.e. disease 
genotypes) are informative, therefore it is reasonable to use e.g. the number of 
independent pairs (for a test statistic that is based on relative pairs) as a weighting 
factor (Sham 1998). For linkage analysis of quantitative traits, such as height, the 
information of an individual depends also on the phenotypic value. For variance 
components analysis, all genotyped and phenotyped non-founders can contribute 
information, provided there is at least one other genotyped and phenotyped family 
member besides his/her parents. For all included studies, the number of genotyped 
and phenotyped individuals was available (table 23). This was not presented 
separately for founders and non-founder, and further details regarding family 
structures could not be obtained from most authors. Therefore, the weighting was 
performed by using the number of genotyped and phenotyped individuals in each 
study (regardless of founder status).  
 If more detailed information on the family structures had been available, this 
could have been incorporated in an approach to calculating the relevant sample 
size. Tang and Siegmund (2001) showed that for variance components analysis of 
quantitative, oligogenic traits in nuclear families, the power of a sibship of size s 
is approximately the same as of s(s-1)/2 independent sib pairs. This justifies 
weighting k sibships of size s equally to ks(s-1)/2 independent sib pairs from 
different families. Tang and Siegmund (2001) also showed that in nuclear families 
where parents are also phenotyped and genotyped, the power for variance 
components linkage analysis is higher than without parents. Depending on the 
sibship size this ranges from about 15 % for sib pairs to 7 % for five sibs. So for 
nuclear families with or without parents, an “effective sample size” for VC 
linkage analysis could be calculated based on the approximately equal number of 
independent sib pairs. If family structures do not vary much within a study (as is 
usually the case) this can be used based on just the average family size in a study 
(and not the distribution of family sizes which is rarely provided). This has the 
advantage that it can often be calculated with just the published summary 




Table 23: Family structures and sizes for linkage studies of height. 
First 
author 




















Hirschhorn Botnia 379 47 11 Partly 7 2-18 
Hirschhorn Finland 702 80 99 Partly 4.2 2-13 
Hirschhorn Sweden 683 89 94 Partly 4.1 2-11 
Hirschhorn Sanguenay-
Lac-St.-Jean 
347 2 61 Partly 6.7 3-15 
Perola combined 580 0 247 No 2.5 NR 
Wiltshire - 1377 0 573 No 2.4 NR 
Xu - 962 34 166 Yes 4.8 NR 
Deng - 630 53 0 Yes 11.9 3-99 
Geller & 
Dempfle 




























1252 0 NR1) No NR NR 
Wu Asians 1069 0 NR1) No NR NR 
1)it was only reported that the total number of families in all 8 data sets was 2508, and the average 






 Other approaches to defining an appropriate effective sample size in linkage 
studies have also been described, especially in the context of meta-analysis. For 
meta-analyses of Bipolar Disorder and Schizophrenia (Levinson et al. 2002), the 
square root of the number of genotyped cases in each sample was used as the 
weighting factor for the respective study. For accompanying power analysis, they 
simulated samples of families which contained one ASP each (which is 
computationally easier and allows for easier interpretation of genetic model 
parameters). The number of ASP families was chosen to represent approximately 
equal linkage information to the samples of pedigrees of different size and 
structure as the original samples. Based on detailed information from one 
Schizophrenia linkage study, they estimated the equivalent number of independent 
ASPs as 1.39 times the number of genotyped cases minus the number of 
pedigrees. Such an approach is only reasonable if the pedigree structures and sizes 
are known in some detail and ideally, the appropriate conversion factor (here 
1.39) should be determined for each study. They did not investigate whether the 
weighting of studies would be more powerful by using the equivalent number of 
independent ASPs as the effective sample size instead of using the number of 
genotyped cases (as they did for the actual meta-analysis).  
 
6.3.5  Ethnicity and heterogeneity 
Genetic heterogeneity between samples might lead to inconsistent results across 
studies. One important reason for heterogeneity could be the presence of causal 
alleles at very different frequencies in different populations, which would lead to 
linkage signals only in some populations but not in others. Ethnically 
homogeneous samples would reduce the risk of such genetic heterogeneity. Most 
of the samples analyzed for linkage to adult stature were of Caucasian origin, only 
the sample from the NHLBI Family Blood Pressure Program (Wu et al. 2003) 
includes three non-Caucasian sub-samples (African American, Asian and 
Mexican American), this supports the expectation that at least some common 
genetic effects can be identified in this sample. A limitation of meta-analysis 
methods that use only p-values is that no formal test for heterogeneity can be 
performed as there is no sensible way to obtain effect sizes from each study. The 






6.4.1 Comparison of Fisher’s method and weighted and unweighted inverse 
normal meta-analysis 
Figure 9 shows the results of the three applied meta-analysis methods on 
chromosomes 1 to 22: Fisher’s method and the weighted and unweighted inverse 
normal meta-analyses. Table 24 gives the LOD scores of the different meta-
analysis methods on selected chromosomes. In this comparison, it has to be kept 
in mind that on such a real data set, no general conclusions regarding power or 
type 1 error can be drawn, since the complex genetic architecture of human stature 
is currently not known in detail. Thus no genes are definitely known to be 
involved in the genetic regulation of height, nor can any genomic region be 
considered as not containing any genes of relevant effect on height. 
 
Table 24: LOD scores of different meta-analysis methods on selected chromosomes 
  Maximum LOD in the region 
Chromosome Approximate 
position of maximum 
LOD (cM) 




3 144-147 1.82 2.6 2.31 
5 130-138 1.92 1.25 1.27 
6 157 4.44 3.4 3.33 
7 175 3.63 4.59 4.13 
9 62 3.95 4.26 4.08 
12 64-65 4.12 3.95 4.08 
13 98-99 2 1.71 1.34 
14 63-66 2.93 1.73 1.41 
15 98-101 2.01 2.52 2.66 
17 76-77 2.24 2.26 2.0 









Figure 9: LOD scores obtained by the three different meta-analysis methods on chromosomes 1-
22, the weighted and unweighted Z-score combination method and Fisher’s method.  
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 In general, for these VC LOD scores, the three methods give very similar 
results with the weighted and unweighted inverse normal methods even more 
similar and Fisher’s method sometimes a bit different. The unweighted inverse 
normal method often gave slightly higher scores than the weighted equivalent. For 
the chromosomes with LOD scores above 3, Fisher’s method gave the highest 
meta-analysis LOD scores on chromosomes 6 and 12 whereas on chromosome 7 
and 9 both inverse normal methods had higher LOD scores. The highest peaks 
differed in magnitude by more than 1, e.g. on chromosome 6 Fisher’s method 
gave a maximum LOD score of 4.44, while the weighted inverse normal method 
had only 3.33. On chromosome 7, a similar difference is seen between Fisher’s 
method (maximum LOS score of 3.63) and the unweighted inverse normal 
method with 4.59. 
 On other chromosomes with lower meta-analysis LOD scores, even slightly 
larger differences exist between the methods: on chromosome 14, Fisher’s method 
gives a maximum LOD score of 2.93 while the weighted inverse normal method 
reaches only 1.41.  
 But while the magnitude of the maxima may differ, overall the results are 
very similar and no method gives the highest LOD scores for the majority of 
regions. 
 The location of regional maxima is also in almost all cases identical or just 1-
2 cM apart. Only on chromosome 20, the location of the maximum LOD score 




the inverse normal methods reach their chromosome-wide maximum at 30 cM, 
while Fisher’s method has the maximum at 62 cM. 
 
6.4.2 Comparison of meta-analysis results with individual results 
Figure 11 shows the LOD scores of all individual scans and the meta-analysis 
LOD score for Fisher’s method. For ease of presentation, just one meta-analysis 
method is presented in these graphs.  
 





















Figure 11: Comparison of LOD scores of the individual study samples (different colors, see 
legend above) and meta-analysis (Fisher’s method, bold red line). 
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 The meta-analysis yields LOD scores above 3 on chromosomes 6, 7, 9 and 
12. The maximum LOD scores (Fisher’s method) are 4.44 on chromosome 6 at 
157 cM, 4.12 on chromosome 12 at 64 cM, 3.95 on chromosome 9 at 62 cM and 
3.63 on chromosome 7 at 175 cM. The next highest LOD score is 2.93 on 
chromosome 14 at 66 cM. 
 There are several instances where interesting regions and peaks in one or 
more scans are confirmed by the meta-analysis. The chromosome 6 region is 
significant in 2 scans (Hirschhorn et al. (2001), Botnia sample and Xu et al. 
(2002) ), but has LOD scores below 1 in the rest of the scans. Similarly for the 
chromosome 7 region, which was significant in the scan by Hirschhorn et al. 
(2001, Swedish sample) and close to significance with a LOD score of 2.91 in the 
scan by Perola et al. (2001), but failed to show any evidence for linkage in the 
other genome scans (LOD scores below 1). Even more marked is this on 
chromosome 12 where a significant LOD score was seen in the Finland sample 
(Hirschhorn et al. 2001), and only two other scans (Geller et al. 2003; Xu et al. 
2002) obtained LOD scores above 1. So the regions which turn out to be 
significant in the meta-analysis were not considered to be “replicated” by the 
majority of available genome scans in the original publications.  
 On the other hand, some regions which show similar patterns of suggestive or 
even significant linkage peaks in one or more scans are not confirmed in meta-
analysis. Most of the regions with suggestive linkage in only one scan are not 
confirmed, e.g. on chromosomes 1 and 8, and significant linkage in just one scan 
is often not quite substantiated by meta-analysis, e.g. on chromosomes 3 and 13, 
which showed evidence for linkage in the scans by Wiltshire et al. (2002) and 
Hirschhorn et al. (2001, Finland sample), respectively. Also regions that were 
suggestive in two scans such as on chromosome 5 do not turn out significant in 
the meta-analysis, but reached only a combined LOD score of 1.9. 
 And finally, the meta-analysis also reveals regions which were not significant 
in any scan and not identified as relevant in the individual publications. This is 
most notably the case on chromosome 9, where no scan gave significant results 
but two reached LOD scores above 2 (Hirschhorn et al. (2001, Botnia sample) and 
Xu et al. (2002), third and second highest peak, LOD scores 2.01 and 2.09, 
respectively) and several with LOD scores above 1. This region had a meta-




Botnia peak without considering the other results for this region published until 
then. To a lesser extent this occurred also on chromosomes 15 and 20 where all 
genome scans had LOD scores below 2 but the meta-analysis gives a LOD score 
of 2 on chromosome 15 (even 2.66 with the weighted inverse normal method) and 
2.48 on chromosome 20 (2.91 with the unweighted inverse normal method). Both 
these regions were not among the highest in any individual scan and thus not 
discussed as potentially relevant. In the same region on chromosome 20, the 
Thompson et al. (1995) scan, which could not be included, also had its smallest p-
value, so the total evidence for linkage would probably be even higher. 
 Another interesting aspect is the location of the meta-analysis maximum in 
relation to the positions of the maxima of the individual scans. In many cases, the 
meta-analysis reaches its maximum LOD score very close to the position of the 
maximum of the one or few significant individual linkage results, as can be seen 
nicely on chromsomes 6, 12 or 14. In some cases however, much smaller LOD 
scores, which are by themselves not significant, nevertheless lead to a noticable 
shift in the location of the meta-analysis maximum compared to the position of 
one prominent and dominating individual linkage peak. This is e.g. evident on 
chromosomes 7 or 17. Finally, in some instances, e.g. on chromosome 9, there is 
no dominating individual linkage peak, but rather several moderate linkage results 
spread over a considerable region, which leads to a broad meta-analysis peak, 
which all the same has a pronounced maximum. 
 Overall, the meta-analysis gives new insights and confirms or refutes the first 
impressions gained from casual inspection and comparison of individual results. 
 
6.5 Discussion 
6.5.1 Comparison of Fisher’s method and weighted and unweighted inverse 
normal meta-analysis 
The three different meta-analysis methods give very similar results in this 
example. Since only variance components LOD scores were available from the 
individual studies, these were transformed to p-values and all three applied meta-
analysis methods are techniques to combine p-values of independent tests. Thus a 
certain similarity of results was expected. Conclusions regarding power or type 1 





6.5.2 Comparison of meta-analysis results with individual results 
A formal, stringent meta-analysis has important advantages over the casual 
inspection of individual results or a loosely defined “replication” approach. All 
available data is incorporated and statistically valid results are reached. This can 
result in confirmation or non-confirmation of regions that showed linkage in one 
of the individual studies and can even reveal new linked regions, which did not 
display prominent linkage in any individual study. 
 In this meta-analysis of linkage genome scans for adult height, including 17 
different samples, there are three important regions which showed linkage in one 
or more scans and were confirmed in the meta-analysis: the chromosome 6 region 
showed significant linkage in two samples, but had LOD scores below 1 in the 
rest of the scans. Similarly, a region on chromosome 7 previously showed one 
significant linkage, one study was close to significance, while the others all had 
LOD scores below 1 in this region. Finally on chromosome 12 again one study 
displayed significant linkage, and only two others reached LOD scores above 1. 
Using a simple replication criterion, the total of these individual results might not 
have been interpreted as convincing evidence for linkage. For these three regions 
on chromosomes 6, 7 and 12, only one or two of the 17 separate genome scans, 
showed strong linkage, while most scans obtained LOD scores below 1, therefore 
the results could easily be interpreted as false positives or as caused by substantial 
genetic heterogeneity between samples. 
 On the other hand are genetic regions which on first impression show similar 
patterns of individual results, but do not reach significance in the meta-analysis. 
This is particularly the case for most regions showing suggestive linkage in only 
one scan which are often not confirmed in meta-analysis, e.g. on chromosomes 1 
and 8. Even regions with significant linkage in only one scan are often not 
confirmed in meta-analysis, e.g. on chromosome 3 (around 20 cM) or on 
chromosome 13.  
 Finally, there are some regions which did not show significant linkage in any 
individual scan, like the region on chromosome 9 where two genome scans 
showed suggestive linkage and several others had LOD scores above 1. A 
comparable pattern was observed on chromosome 5, where also two individual 




not-significant result. In such cases only a formal meta-analysis allows a 
statistically correct interpretation of all available evidence. 
 
6.5.3 Conclusions for the genetics of stature 
The significant results of this meta-analysis of linkage genome scans of adult 
stature may lead the way to important insights into the genetics and molecular 
mechanisms of human growth. Ten chromosomal regions yielded meta-analysis 
LOD scores of at least 2 (and chromosome 5 had a LOD score of 1.92), four of 
these had LOD scores above 4 (with at least one of the meta-analysis methods). 
This could be compatible with the results of segregation analyses (Ginsburg et al. 
1998) that found a combination of major gene and polygenic inheritance of height 
and goes in line with the polygenic concept that small additive effects at many 
loci lead to an approximately normally distributed phenotype in the general 
population. The results of the meta-analysis are consistent with the expectation 
that there are several genes with effects that are detectable in linkage analysis 
(albeit only in large samples). The combined sample size of genotyped and 
phenotyped individuals in this meta-analysis was more than 14000. This means 
that the power to detect genes with large effect (high locus-specific heritability) 
should be very high. Genetic regions with meta-analysis LOD scores around 4 
might contain genes with medium locus-specific heritability, i.e. either relatively 
rare variants with moderate effect or rather common alleles with smaller effect, 
while regions with LOD scores ~2 might harbor genes with lower locus-specific 
heritability or no genes influencing height at all (i.e. false positives). Candidate 
genes for human stature in the regions identified in this meta-analysis would be 
expected to contribute to the normal variation in height in the general population. 
Additionally, there are probably many genes which are essential for growth, and 
as such do not show relevant variation in the normal population. In these genes, 
mutations might lead to extreme phenotypes (very rare monogenic diseases with 
severe short stature or lethal mutations) and possibly no frequent functional 
polymorphisms exist. This might be the case for growth hormone related genes 
(e.g. GHR, GH1, GHRHR, GHSR, see table 25) where rare mutations have been 
identified which lead to extremely short stature, but no common variants with 
subtle effect are currently known in the general population. Such genes would not 




based studies in this meta-analysis. Accordingly, in the chromosomal regions of 
the growth hormone secretagogue receptor gene (GHSR, chr. 3, approximately 
183 cM), the growth hormone receptor gene (GHR, chr. 5, 60 cM) and the growth 
hormone releasing hormone receptor gene (GHRHR, chr. 7, 49 cM) the meta-
analysis LOD scores are below 0.5. Near the growth hormone 1 gene (GH1, chr. 
17, 82 cM) on the other hand, the meta-analysis obtained a maximum LOD score 
of 2.26 (at 77 cM), which might indicate that there are common polymorphisms in 
the GH1 gene or its regulatory region (promoter) which influence also normal 
variation in stature. Different results and the identification of additional growth 
related loci could therefore be expected with selected samples (short or tall 
stature) as opposed to samples from the normal population. Similarly, the genetic 
analysis of variation in stature can be supplemented by the study of genetic 
syndromes which include short or tall stature among their cardinal features, such 
as Noonan Syndrome (OMIM 163950), Prader-Willi Syndrome (OMIM 176270) 
and many others. In some cases, genes responsible for these syndromes might also 
have alleles which influence normal growth variation or the whole syndrome is 
caused by microdeletions which include dozens of genes (e.g. Prader-Willi 
Syndrome), just one of which might be involved in growth regulation. E.g., the 
short stature seen in Léri-Weill dyschondrosteosis (LWD, OMIM 127300) and 
Ullrich-Turner Syndrome is caused by haploinsufficiency due to heterozygous 
deletions or mutations of the SHOX gene or its regulatory regions (Attie 2000; 
Benito-Sanz et al. 2005; Rao et al. 1997). Such mutations or deletions in the 
SHOX gene seem to be responsible for a fraction of patients with idiopathic short 
stature as well, with estimates ranging from 1% to 22% (Huber et al. 2004; 
Morizio et al. 2003; Rappold et al. 2002; Schneider et al. 2005; Stuppia et al. 
2003) with the largest studies to date reporting only 2-2.4% (Rappold et al. 2002; 
Schneider et al. 2005). The SHOX gene is located in the pseudoautosomal region 
of the X- and Y-chromosome (Xp22), which was not analyzed in this meta-
analysis as only Deng et al. (2002) reported X-chromosomal linkage analysis. The 
genetic regions of Noonan and Prader-Willi-Syndrome had meta-analysis LOD 
scores below 0.5, thus not supporting the possibility of relevant alleles for normal 
height in these regions. 
 Many candidate genes especially for stature and growth related phenotypes 




comprehensive list of some examples). These include genes of the growth 
hormone-IGF-system (e.g. GH1, GHRHR, GHSR, IGF-1), genes regulating 
skeletal development and bone formation (e.g. COL1A1, BMP2, FGFR3, VDR), 
genes involved in pituitary development (e.g. POU1F1, PROP1, LHX3, HESX1), 
or genes related to sex hormones (ESR1, CYP17, CYP19). Studies relating to these 
candidate genes and monogenic forms of growth disorders have been extensively 
reviewed (e.g. by Palmert and Hirschhorn 2003; Castro-Feijoo et al. 2005; Kant et 
al. 2003).  
 These genes are considered candidate genes for height because of the 
knowledge about the gene function and their involvement in growth processes. 
Genome scans on the other hand have the advantage that no prior knowledge on 
gene function is required, so new candidates which are not obviously related to 
the phenotype in question can be identified. Future research should therefore 
investigate especially genes in linkage regions identified in this meta-analysis for 
their potential involvement in growth regulation. Some known candidate genes in 
linked regions are BMP10 (chromosome 2), ESR1 (chromosome 6), VDR, KRAS 
and IGF-1 (all chromosome 12), GH1 (chromosome 17) and BMP2 (chromosome 
20). These might be responsible for the observed linkage peaks in this meta-
analysis. For other significant linkage regions, such as those on chromosomes 7 
and 9 and smaller linkage peaks such as on chromosomes 14 and 15, no obvious 
candidate genes have yet been identified but careful consideration of known genes 




Table 25: Candidate genes for height.  
Chromosome Cytogenetic region 
Position 
(cM) Gene name Context References 




Feijoo et al. 
(2005) 
3 3p26 19 
Basic helix-loop-
helix domain 
containing, class B, 
2 (BHLHB2, DEC1) 
 Wiltshire et al. (2002) 









et al. (2003) 
3 3p22-p21.1 69 
Parathyroid 















Pantel et al. 
(2006) 





et al. (2004) 














Schuit et al. 
(2004) 








Feijoo et al. 
(2005) 
7 7p12-p13 66 
Insulin-like growth 
factor binding 




Deal et al. 
(2001)  
8 8p21-23 37 Early growth response (EGR3)  
Deng et al. 
(2002) 
10 10q24.3 125 
Cytochrome P450, 
family 17, subfamily 




Zmuda et al. 
(2001) 





Lei et al. 
(2005) 






Miyake et al. 
(1999) 
12 12p12.1 45 KRAS, Noonan Syndrom  
Schubbert et 
al. (2006) 
      




Chromosome Cytogenetic region 
Position 
(cM) Gene name Context References  
12 12q12-q14 62 Vitamin D receptor (VDR) 
Skeletal 
development 
Suarez et al. 
(1997; 1998); 
Tao et al. 
(1998); 
Minamitani 
et al. (1998); 
Ferrara et al. 
(2002); van 
der Sluis et 
al. (2003) 












 Cassidy (1997) 
15 15q21.1 45 
Cytochrome P450, 
family 19, subfamily 




Ellis et al. 
(2001) 
17 17p11.2 44 Zinc finger protein 179 (ZNF179)  
Deng et al. 
(2002) 
17 17q21.3-q22.1 69 
Collagen type 1 
alpha 1 (COL1A1) 
Skeletal 
development 
Garnero et al. 
(1998); Long 
et al. (2004) 




Horan et al. 
(2003) 
17 17q24-25 101 
Growth factor 
receptor-bound 
protein 2 (GRB2) 
 Deng et al. (2002) 
19 19q13.32 75 Luteinizing hormone beta (LHB) 
Sex 
hormones 
Raivio et al. 
(1996) 




























Gedeon et al. 
(1999) 
 









Prospects for meta-analysis of linkage studies 
For complex phenotypes, which are influenced by several genetic and 
environmental factors, the sample sizes achievable within one study are generally 
too small to yield convincing evidence for genetic linkage (Altmüller et al. 2001). 
However, many common complex diseases are investigated by numerous groups 
worldwide and meta-analysis of all available studies can result in sufficient power 
with combined samples (Conneally 2003). A growing number of published meta-
analyses of linkage genome scans for various complex diseases has shown the 
increasing interest in such scientific co-operations and the good prospects for 
applications. 
 
Different approaches for meta-analysis of linkage studies 
Depending on the degree of detail in which data can be obtained for a meta-
analysis, different statistical approaches are possible. Accordingly, the results that 
can be achieved by different methods of meta-analysis yield more or less detailed 
information about the combined effect and may include a more precise location 
estimate. If the complete family information, genotype and phenotype data of all 
samples are available, a sensible primary analysis can be performed which yields 
effect size estimates and their variances. These can be combined in traditional 
fixed or random effects meta-analysis, together with heterogeneity tests, to obtain 
combined effect estimates and confidence intervals which in turn give refined 
location estimates. If such detailed data cannot be obtained, methods such as the 
proposed weighted combination of NPL scores (Loesgen et al. 2001; Dempfle and 
Loesgen 2004), the GSMA (Wise et al. 1999) or Fisher’s method (Fisher 1932) 
for the combination of p-values still require results for all tested markers or 
genetic locations, which usually will have to be requested from the authors of 




but only tests of significance, and while Fisher’s method and the weighted 
combination of NPL scores can refine the locations of the best combined results, 
the GSMA gives only one p-value per 30 cM bin, thus indicating only very broad 
linkage regions. Only the MSP method (Badner and Gershon 2002a), a variation 
of Fisher’s method, can be performed with just the usually published data, i.e. the 
smallest p-values in a genetic region with their approximate locations. Again, no 
effect estimation for the combined sample is possible and the resulting p-value 
applies to the largest region investigated in one of the original studies.  
 
Heterogeneity  
An area of further research are useful heterogeneity tests for linkage genome 
scans. A random effects meta-analysis, e.g. on the number of alleles shared 
identical by descent (IBD) between affected sib pairs (ASPs) might be advisable if 
heterogeneity between samples is suspected, but is only practically feasible if the 
detailed data such as the family specific IBD estimates are available (McQueen et 
al. 2005). This will usually only be the case for close collaborations where the 
complete raw data (family structures, genotypes, phenotypes) are accessible. Such 
entire data is also necessary for standard heterogeneity tests, which have low 
power for whole genome scans. A heterogeneity test for the Genome Search 
Meta-Analysis statistic (GSMA) was recently proposed using just the data 
commonly available for meta-analysis (Zintzaras and Ioannidis 2005), its power 
however has not been investigated in comparison to other approaches. If potential 
sources of heterogeneity, such as different ethnicities between study samples, are 
known, a useful strategy would be to perform meta-analyses for presumably more 
homogeneous subsets of samples from the same population as well as for all study 
samples. Additionally, methods that are explicitly designed to be powerful against 
specific alternatives (e.g. linkage to a certain region in only a subset of studies, i.e. 
only some of the null hypotheses are false) may be preferable. This includes 
truncation methods (variants of Fisher’s method (Olkin and Saner 2001; Zaykin et 
al. 2002)), which consider only p-values below a certain threshold and the number 







Proposed new meta-analysis method for linkage genome scans 
A new statistical method for meta-analysis of linkage studies was proposed by  
Loesgen et al. (2001) which is, for non-parametric linkage analysis of ASPs, 
equivalent to a fixed effects meta-analysis on the number of alleles IBD. As such, 
study specific parameter estimates are weighted by the inverse of their variances 
(determined by the sample size) to obtain a combined estimate. The loss of power 
in non-parametric multipoint linkage analysis, which occurs for locations at which 
there is no fully informative marker, corresponds to a reduction in effective 
sample size (Guo and Elston 1999; Schork and Greenwood 2004). Therefore, 
weighting schemes are proposed which account for such lower information 
content. This becomes especially important for meta-analysis since different 
studies usually employ different sets of markers and information content within 
each study varies between genetic locations. Therefore the weighting factor for 
each study (representing the effective sample size) does not have to be constant 
throughout the genome but can vary by location. 
 
Power comparison 
The new meta-analysis method proposed by Loesgen et al. (2001) is compared to 
other approaches (GSMA, Fisher’s method and the truncated product method) in a 
simulation study (Dempfle and Loesgen 2004). This shows that the incorporation 
of study specific characteristics (such as information content and sample size) in a 
meta-analysis of a qualitative trait by direct weighted combination of NPL scores 
has better power than previously used methods that combine p-values. Different 
weighting schemes for the proposed NPL score combination method are 
investigated and a weighting with information content and sample size has best 
power for the simulated scenarios. An important characteristic of the NPL 
combination method is that for studies with the same design (e.g. ASP studies) 
appropriate weighting by sample size leads to the same result as would be 
obtained if the raw genotype data were analyzed together. P-value methods on the 
other hand, are sensible to different sample sizes between studies and yield 
different results if the same families are split up into samples in different ways. 
The loss of power for non-parametric linkage methods that occurs if markers are 
not completely informative can be reduced by using the NPL combination method 




Application of the meta-analysis method: asthma 
The meta-analysis of four whole genome and five candidate region linkage studies 
on asthma revealed no region of significant linkage to this phenotype (Loesgen et 
al. 2001). The lowest p-values were obtained on chromosomes 1, 11 and 19. A 
possible reason for this lack of significant results is that the combined sample size 
is still too small, as the whole genome scans included only 340 families, and for 
the chromosome 5 candidate region 567 families were available. Given the 
moderate power of ASP linkage analysis for complex diseases, this seems to be 
insufficient to reliably identify genes involved in asthma susceptibility. The only 
asthma susceptibility gene that was yet identified by positional cloning, the 
ADAM33 gene (Van Eerdewegh et al. 2002), was identified in a genome scan of 
460 families and it seems plausible that samples of at least this size are necessary 
to identify this and other asthma susceptibility genes. Different methodological 
issues were explored in this meta-analysis where individual data was available. 
Besides a demonstration of the feasibility and practical application of different 
weighting schemes for NPL scores, a comparison with the GSMA method was 
performed, and effects of marker map construction for the combined marker sets 
were investigated. While inaccuracies of the assumed marker map can lead to bias 
in multipoint linkage analysis, nowadays very precise (linkage and physical) maps 
are available (Kong et al. 2004; Duffy 2006) so that this does not impose serious 
problems for meta-analysis. 
 
Framingham Heart Study genome scan for height 
A genome scan for the quantitative phenotype adult height which was performed 
in a sample of extended pedigrees not ascertained for this trait, the Framingham 
Heart Study, yielded suggestive evidence for linkage in several genetic regions 
(Geller et al. 2003). Comparison of these results with previously published 
genome scans for the same phenotype showed remarkable concordance for some 
regions, as well as discordance for regions linked in other studies which were not 
replicated in the current sample. Thus a meta-analysis of all available genome 
scans for height was planned to exactly quantify the combined evidence for 






Meta-analysis of height genome scans 
The available, published genome wide linkage studies for the quantitative 
phenotype adult stature (Perola et al. 2001; Hirschhorn et al. 2001; Wiltshire et al. 
2002; Xu et al. 2002; Deng et al. 2002; Wu et al. 2003; Geller et al. 2003) were 
very well suited for a meta-analysis, as almost all samples were of Caucasian 
origin, all samples were unselected for the phenotype of interest, the same primary 
statistical analysis was used for all individual studies (variance components 
linkage analysis) and all had used the Marshfield map as a reference map. 
However, only LOD scores and sample size for each study were available for the 
meta-analysis, so only methods appropriate for the combination of p-values could 
be applied and no formal heterogeneity test was possible. The three methods used 
(weighted and unweighted inverse normal method and Fisher’s method) gave very 
similar results. The large combined sample size of over 14000 phenotyped and 
genotyped individuals enabled the identification of significant linkage to 
chromosomes 6, 7, 9 and 12 (with LOD scores greater 4) and revealed several 
“suggestive” regions (another six regions with LOD scores greater 2). This is well 
compatible with the results of segregation analyses which support the concept of 
stature as a phenotype with mostly polygenic but also major gene inheritance. 
 
Conclusions for meta-analysis of linkage studies 
The role of meta-analysis in genetic epidemiology will become more important as 
it is realized that for complex diseases that have a high impact on public health 
but are influenced by many factors with small effects, a single study alone cannot 
have sufficient power. While large studies are in progress, the valuable data from 
genome scans that were too small individually but are already completed should 
not be wasted but exploited efficiently. Thus, there are good prospects for future 
applications of meta-analysis in the area of genetic linkage studies for complex 
diseases, since scientists are interested in making more use of their already 
collected and published data to obtain higher power through increased sample 
sizes. Among the first efforts towards this goal, some successful meta-analyses of 
complex diseases have been published in the last few years (e.g. Badner and 
Gershon 2002b; Cox et al. 2001) and the application to the phenotype adult height 
presented here shows the great potentials of meta-analyses that include large 




and depending on the extend of co-operation and data sharing, different methods 
are available. The weighted combination of NPL scores investigated here is a 
useful tool for research in genetic epidemiology, as it is easily applicable, and has 
more power than other suggested methods. It does not need raw data but leads to 
the same results as a pooled analysis that considers systematic differences in 
markers and uses only the output commonly given by model-free linkage analysis 
software. If less detailed results are available (such as LOD scores from variance 
components linkage analysis of quantitative traits), methods that are based on the 
combination of p-values are useful, as demonstrated in the meta-analysis of 
height. More research on sensible heterogeneity tests for meta-analysis of linkage 
genome scans would be desirable. A further increase of published meta-analyses 










Linkage genome scans for genetically complex diseases have low power with the 
sample sizes that were often used in the past, and hence meta-analysis of several 
scans for the same disease might be a promising approach. Appropriate data are 
now becoming accessible as many groups worldwide investigate common 
diseases. The aim of this thesis is to extend and evaluate statistical methodology 
for meta-analysis. In addition, two meta-analyses of linkage genome scans for the 
complex phenotypes asthma and adult stature are performed and discussed. 
 In the first part of this thesis, an overview of available statistical methods and 
current applications is given. Important differences between studies, which may 
lead to heterogeneity and should be accounted for in a meta-analysis, are 
reviewed. Some available statistical tests for heterogeneity between linkage 
studies are presented and their limitations for genome scans are discussed. A new 
meta-analysis method is introduced which is based on a weighted combination of 
non-parametric linkage scores. Its relationship to traditional fixed effects meta-
analysis of combining parameter estimates from different studies weighted by the 
inverse of their respective variances is described. Recombination and low 
informativity of markers lead to a reduction of the effective sample size in 
multipoint linkage analysis. A locus specific weighting of individual studies with 
this effective sample size is therefore proposed. In a simulation study, the power 
of different methods to combine multipoint linkage scores, namely Fisher’s p-
value combination (Fisher 1932), the truncated product method (Zaykin et al. 
2002, a variant of Fisher's method), the Genome Search Meta-Analysis (GSMA, 
Wise et al. 1999) method and the proposed weighting methods were compared. In 
particular, the effects of different genetic marker sets and sample sizes between 
genome scans were investigated. The weighting methods explicitly take those 





 The proposed meta-analysis method was applied to four linkage genome 
scans for the phenotype asthma and five studies of a candidate genetic region. 
Multipoint nonparametric linkage analysis is performed and different weighting 
schemes are used to combine the score statistics of individual studies to an overall 
statistic. For comparison, the GSMA method is also applied to the same data sets. 
For meta-analysis of linkage studies, a common map of genetic markers is 
necessary to align results obtained in different studies with different markers. In 
this meta-analysis, the effects of map uncertainties were evaluated. The latest 
versions of available combined physical and linkage maps are very precise and the 
small potential map errors that are left do not have relevant impact. This meta-
analysis of nine asthma linkage studies does not identify significant regions of 
genetic linkage to asthma. A still rather small size of the combined samples may 
be the reason for low power to identify susceptibility genes for the complex trait 
asthma.  
 The statistical methods that can be applied for a meta-analysis of linkage 
studies depend crucially on the available data, especially any additional 
information besides the usually reported linkage statistics. For the meta-analysis 
of linkage genome scans for the highly heritable trait adult height, only LOD 
scores from variance components linkage analysis, which are measures of 
significance and not effect estimates, could be obtained.  Thus, Fisher’s method 
and a weighted and unweighted variant of the inverse normal method were 
applied. Initially, a linkage genome scan for this quantitative trait was performed 
in the extended pedigrees of the Framingham Heart Study. A variance 
components linkage analysis in this sample unselected for height gave evidence 
for linkage in several regions. All markers showing a LOD score greater than 1 in 
this analysis correspond to previously reported linkage regions, including 
chromosome 6q with a maximum LOD score of 2.45 and chromosomes 9, 12, 14, 
18 and 22. Following this observation, a meta-analysis of all previously published 
genome scans for adult stature was planned. Genome scan results of 17 separate 
samples reported in seven publications and comprising more than 14000 
phenotyped and genotyped individuals could be obtained in sufficient detail to be 
included in the meta-analysis. The comparison of meta-analysis results with 
individual studies shows that only a formal meta-analysis can exactly quantify the 




results as replication or non-replication. Significant linkage of stature is observed 
on chromosomes 6, 7, 9 and 12 (LOD scores >4) and suggestive linkage with 
LOD scores >2 is obtained in six additional genetic regions. This is well 
compatible with the concept of height as a mostly polygenic trait for which also 











Kopplungsgenomscans für genetisch komplexe Krankheiten haben mit den 
bislang üblichen Fallzahlen oft nur eine geringe statistische Power, daher sind 
Meta-Analysen von mehreren Genomscans für die gleiche Krankheit ein 
erfolgversprechender Ansatz. Passende Datensätze werden zunehmend verfügbar, 
da weltweit viele Gruppen genetische Studien zu den häufigsten Krankheiten 
durchführen. Ziel dieser Arbeit ist es, statistische Methoden der Meta-Analyse 
weiter zu entwickeln und zu evaluieren. Weiterhin werden zwei Meta-Analysen 
von Genomscans für komplexe Phänotypen, Asthma und Körpergröße, 
durchgeführt.  
Im ersten Teil dieser Dissertation wird ein Überblick über aktuelle 
Anwendungen und bisherige statistische Methoden gegeben. Wichtige 
Unterschiede zwischen Studien, die zu Heterogenität führen können und in einer 
Meta-Analyse berücksichtigt werden sollten, werden erörtert. Einige vorhandene 
statistische Tests auf Heterogenität zwischen Kopplungsstudien werden 
vorgestellt und ihre Einschränkungen bei der Anwendung auf Genomscans 
diskutiert. Eine neue Methode für Meta-Analysen von genetischen 
Kopplungsgenomscans, die auf einer gewichteten Kombination von nicht-
parametrischen Kopplungsstatistiken basiert, wird vorgestellt. Ihr Zusammenhang 
mit herkömmlicher „fixed-effects“ Meta-Analyse für Parameterschätzer wird 
erläutert. Rekombinationen und geringe Informativität genetischer Marker führen 
in der multipoint Kopplungsanalyse zu einer Reduzierung der effektiven Fallzahl. 
Eine locusspezifische Gewichtung der einzelnen Studien mit dieser effektiven 
Fallzahl wird vorgestellt. In einer Simulationsstudie wurde die statistische Power 
verschiedener Meta-Analyse Methoden für multipoint Kopplungsergebnisse 
verglichen. Dabei wurden die Methode nach Fisher zur Kombination von p-
Werten (Fisher 1932), die „truncated product method“ (Zaykin et al. 2002, eine 




(GSMA, Wise et al. 1999) und die vorgeschlagenen Gewichtungsmethoden 
angewandt. Insbesondere wurden die Einflüsse unterschiedlicher genetischer 
Marker und Fallzahlen zwischen Genomscans untersucht. Die 
Gewichtungsmethoden berücksichtigen diese Unterschiede explizit und haben 
eine höhere statistische Power in den untersuchten Szenarien als die anderen 
Methoden.  
Die vorgeschlagene Meta-Analyse Methode wurde auf vier 
Kopplungsscans und fünf Studien einer Kandidatengenregion für den Phänotyp 
Asthma angewandt. Zunächst wurden nicht-parametrische multipoint 
Kopplungsanalysen der Einzelstudien durchgeführt und die Einzel-Teststatistiken 
dann mit verschiedenen Gewichtungsmethoden zu einer Gesamtstatistik 
zusammengefasst. Zum Vergleich wurde auch die GSMA Methode auf dieselben 
Daten angewandt. Für eine Meta-Analyse von Kopplungsstudien benötigt man die 
relative genetische Position aller in den verschiedenen Studien verwendeten 
Marker zueinander, also eine gemeinsame genetische Karte. Die Bedeutung von 
Ungenauigkeiten der genetischen Karte wurde daher in dieser Studie untersucht. 
Die neuesten Versionen der zur Verfügung stehenden kombinierten 
physikalischen und genetischen Karten sind sehr präzise und die möglicherweise 
noch enthaltenen geringen Fehler haben keinen relevanten Einfluss auf eine Meta-
Analyse. Die Meta-Analyse der neun Asthma-Studien ergab keine signifikanten 
Hinweise auf Kopplung. Die relativ geringe Gesamtstichprobengröße ist ein 
möglicher Grund für geringe statistische Power zur Identifikation von 
Suszeptibilitätsgenen für die genetisch komplexe Krankheit Asthma.  
 Welche statistischen Methoden für eine Meta-Analyse verwendet werden 
können, hängt stark von den zur Verfügung stehenden Daten ab, insbesondere 
welche weiteren Informationen neben den üblicherweise berichteten 
Teststatistiken vorhanden sind. Für die Meta-Analyse von Kopplungsgenomscans 
des Phänotyps Körpergröße standen nur LOD scores aus 
Varianzkomponentenanalysen zur Verfügung, welche Signifikanzmaße, nicht aber 
Effektstärkenschätzer sind. Daher wurden die Methode nach Fisher und eine 
gewichtete sowie ungewichtete Variante der Inversen-Normalverteilungsmethode 
angewandt. Zunächst wurde ein Kopplungsgenomscan dieses quantitativen 
Merkmals in den erweiterten Stammbäumen der Framingham Heart Study 




dieser für Körpergröße nicht speziell ausgewählten Stichprobe Kopplung zu 
mehreren genetischen Regionen. Alle Marker, die in dieser Auswertung einen 
LOD score (Kopplungsteststatistik) größer als 1 zeigen entsprechen schon früher 
berichteten Kopplungsregionen, darunter Chromosom 6q mit einem maximalen 
LOD score von 2,45 und Regionen auf den Chromsomen 9, 12, 14, 18 und 22. 
Auf Grund dieser Beobachtung wurde eine Meta-Analyse aller publizierten 
Genomscans für Körpergröße geplant. Die Ergebnisse von 17 Stichproben (aus 
sieben Veröffentlichungen) mit insgesamt mehr als 14000 phänotypisierten und 
genotypisierten Personen konnten in die Meta-Analyse einbezogen werden. Der 
Vergleich der Ergebnisse der Meta-Analyse mit denen der Einzelstudien zeigt, 
dass nur eine formale Meta-Analyse die Hinweise auf Kopplung genau 
quantifizieren kann und einer ungenauen Einteilung der Ergebnisse im Sinne einer 
Replikation oder Nicht-Replikation vorzuziehen ist. Signifikante Kopplung von 
Körpergröße ergibt sich zu den Chromosomen 6, 7, 9 und 12 (mit Gesamt-LOD 
scores >4) und Hinweise auf Kopplung mit LOD scores >2 finden sich in sechs 
weiteren genetischen Regionen. Dies ist gut vereinbar mit dem Konzept, dass 
Körpergröße hauptsächlich polygen bestimmt ist, daneben aber auch Hauptgene 
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